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ABSTRACT
CRISPR/Cas9 is an attractive platform to poten-
tially correct dominant genetic diseases by gene
editing with unprecedented precision. In the cur-
rent proof-of-principle study, we explored the use
of CRISPR/Cas9 for gene-editing in myotonic dys-
trophy type-1 (DM1), an autosomal-dominant mus-
cle disorder, by excising the CTG-repeat expansion
in the 3′-untranslated-region (UTR) of the human
myotonic dystrophy protein kinase (DMPK) gene
in DM1 patient-specific induced pluripotent stem
cells (DM1-iPSC), DM1-iPSC-derived myogenic cells
and DM1 patient-specific myoblasts. To eliminate
the pathogenic gain-of-function mutant DMPK tran-
script, we designed a dual guide RNA based strategy
that excises the CTG-repeat expansion with high ef-
ficiency, as confirmed by Southern blot and single
molecule real-time (SMRT) sequencing. Correction
efficiencies up to 90% could be attained in DM1-iPSC
as confirmed at the clonal level, following ribonucle-
oprotein (RNP) transfection of CRISPR/Cas9 com-
ponents without the need for selective enrichment.
Expanded CTG repeat excision resulted in the disap-
pearance of ribonuclear foci, a quintessential cellular
phenotype of DM1, in the corrected DM1-iPSC, DM1-
iPSC-derived myogenic cells and DM1 myoblasts.
Consequently, the normal intracellular localization
of the muscleblind-like splicing regulator 1 (MBNL1)
was restored, resulting in the normalization of splic-
ing pattern of SERCA1. This study validates the use
of CRISPR/Cas9 for gene editing of repeat expan-
sions.
INTRODUCTION
Myotonic dystrophy type 1 (DM1, also known as Steinert’s
disease) is an autosomal dominant disease and one of the
most common dominant neuromuscular disorders in adults
with a prevalence ranging from 0.5 to 18.1 per 100,000 in-
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dividuals (1,2). Typically, DM1 patients suffer from pro-
gressive myopathy and myotonia, cardiac conduction de-
fects and cognitive impairments (1). DM1 is caused by the
presence of expanded trinucleotide CTG repeats in the 3′
untranslated region (UTR) of DMPK (myotonic dystrophy
protein kinase) gene on chromosome 19q13.3 (3,4). Disease
severity correlates with the number ofCTG repeats, varying
between 50 to >2000 repeats in severely afflicted DM1 pa-
tients. In contrast, healthy individuals have a limited num-
ber of repeats in the DMPK 3′ UTR (i.e. 5–37 CTG re-
peats). The repeat length increases during the patient’s life-
timewith an intra- or inter-tissue variability (5). In addition,
the repeat size also increases with successive generations
ultimately giving rise to increasingly more severe disease
phenotypes, a phenomenon defined as anticipation (6). The
corresponding DMPK RNA transcripts contain expanded
CUG repeats (designated as CUGexp-RNA) that contribute
directly to the DM1 pathogenesis (7). This occurs primarily
through nuclear sequestration of the so-called muscle blind
like (MBNL) family of splicing factors by the pathogenic
CUGexp RNA. Consequently, this results in the accumula-
tion of ribonuclear foci (NF) in the nuclei of patient’s cells,
one of the quintessential characteristics of DM1 (8,9).
Since DM1 patients suffer from skeletal muscle dysfunc-
tion, it is widely considered as the prime target tissue to as-
sess novel targeted therapies. In the current study, we there-
fore investigated the potential of the clustered, regularly in-
terspaced, short palindromic repeats (CRISPR)/Cas9 sys-
tem to eliminate the pathogenic CTG repeats expansion
from the DMPK gene in DM1 patient-specific myogenic
cells (Figure 1A). The CRISPR/Cas9 system was initially
discovered as a naturally occurring microbial defense sys-
tem that recognizes and cleaves foreign DNA in a sequence-
specific manner (10–12). Since then, it has been adapted
successfully as a versatile RNA-guided gene-editing tool
for mammalian cells (13–15). CRISPR/Cas9-based gene
editing has been shown to enable correction of both re-
cessive and autosomal dominant disorders (16–25). Typ-
ically, gene editing using CRISPR/Cas9 can be achieved
by co-expression of the CRISPR-associated (Cas9) gene
with a chimeric single guide RNA (gRNA) composed of
theCRISPR RNA (crRNA) and the trans-activating crRNA
(tracrRNA).
In the current study, we have proven the ability of
CRISPR/Cas9 to selectively excise trinucleotide repeat ex-
pansions and phenotypically correct DM1 patient-specific
induced pluripotent stem cells (DM1-iPSC) and non-
transformed DM1 patient-specific cells capable of under-
going myogenic differentiation, consistent with the ro-
bust correction of the cellular phenotype. In particular,
the CRISPR/Cas9-based correction was validated in DM1
patient-specific myoblasts and myogenic cells derived from
DM1-iPSCs (26,27). These DM1-iPSCs were subsequently
induced to undergo lineage-specific differentiation to ob-
tainDM1 patient-specificmyogenic cells, myocytes andmy-
otubes. Primarymyoblasts and iPSC-derivedmyogenic cells
have a distinctive capacity towards myogenic differentiation
and are attractive target cells to validate the potential of
CRISPR/Cas9 for gene editing of DM1. Myoblasts are de-
rived from satellite cells that are muscle stem/progenitor
cells capable of generating multinucleated muscle fibres
through cell fusion. Whereas, the iPSC-derived myogenic
cells (iPSC-Myo) used in the present study resemble pri-
mary mesoangioblasts (Mabs) with respect to their abil-
ity to form mature myocytes and myotubes, and based on
their surface markers and transcriptome expression pat-
terns (26,27). Mesoangioblasts are pericyte-derived cells
and regarded as non-canonical precursors of myogene-
sis. Such non-canonical myogenic precursors typically do
not express PAX7, MYF5 or MYOD during their prolif-
eration stage until they are terminally differentiated (28–
31). Mesoangioblasts and iPSC-Myo can extravasate from
the circulation allowing repair of the afflicted degenerating
muscle tissue. Since myoblasts and iPSC-Myo cells are non-
transformed and non-tumorigenic as opposed to immortal-
ized cell lines, they eventually undergo cellular senescence,
consistent with the Hayflick limit that is a characteristic of
bona fide primary cells. Though it is typically more chal-
lenging to achieve efficient gene editing in non-transformed
cells, we observed robust reduction of ribonuclear foci
in the DM1 myoblasts and DM1-iPSC-derived myogenic
cells with up to 40–50% efficiency after CRISPR/Cas9
based gene correction. Consequently, the normal intracellu-
lar localization of the muscleblind-like splicing regulator 1
(MBNL1) was restored resulting, in turn, in the normaliza-
tion of the splicing pattern of the sarco/endoplasmic retic-
ulum Ca2+-ATPase 1 (SERCA1), that is associated with
DM1 pathology. Our study also showed that by using ri-
bonuclear protein (RNP) transfections in DM1-iPSC it is
possible to achieve 90% correction efficiencies without the
need for any selective enrichment step.
This proof-of-concept study validates the use of
CRISPR/Cas9 to genetically correct nucleotide repeat
expansions associated with dominant genetic disorders like
DM1, that cause severe human pathologies. Moreover,
in the current study, we also validated the use of single
molecule real-time (SMRT) sequencing as a comprehensive
and sensitive assay to characterize the efficiency of trinu-
cleotide repeat editing by CRISPR/Cas9. The increased
sensitivity of SMRT sequencing overcomes the limitations
of some conventional strategies. This has implications
to characterize the outcome of gene editing for other
nucleotide repeat disorders.
MATERIALS AND METHODS
Generation of DM1 patient- specific induced pluripotent stem
cells (DM1-iPSCs)
Myoblasts and fibroblasts of DM1 patients were obtained
from a 46-year and 11-year-old female DM1 donors re-
spectively, with their informed consent. The patients dis-
played clinical traits of ptosis, atrophy, muscle weakness,
neck flexors, myotonia, cataract, electrocardiogram con-
duction abnormalities and daytime somnolence. Fibrob-
lasts from a healthy donor were used as controls. The
fibroblasts were cultured in Dulbecco’s modified Eagle’s
medium with high glucose (DMEM-HG, Thermo Scien-
tific) containing 10% inactivated fetal bovine serum (FBS,
Thermo Scientific), 100 IU/ml penicillin and 0.1 mg/ml
streptomycin (Pen-Strep, Thermo Scientific), 1 mM sodium
pyruvate (Thermo Scientific), 1% (v/v)MEMnon-essential
amino acids (Thermo Scientific) and 1 mM L-glutamine
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(Thermo Scientific). The myoblast cells were cultured in
ready to use skeletal muscle cell growth medium with sup-
plements (Cat # C-23060, Promo-cell). Non-self inactivat-
ing retroviral vectors expressing OCT4, SOX2, KLF4 and
cMYC with MoMuLV promoter were used to transduce 1
× 105 cells per well of a six-well dish (32). At 16 h post
transduction, media containing the retroviral particles were
removed and replaced with fresh media, followed by an-
other media change at 48 h. At day 4, the transduced cells
were passaged and plated on a 0.1% gelatin-coated plate.
On day 5, the culture media was changed to hES medium
containing ‘knockout’ Dulbecco’s modified Eagle’s medium
(KO DMEM, Thermo Scientific), 20% ‘knockout’ serum
replacement (KOSR, Thermo Scientific), 1% (v/v) MEM-
Non Essential Amino Acids (MEM NEAA, Thermo Sci-
entific), 2 mM L-glutamine (Thermo Scientific), 50 M
-mercaptoethanol, 100 IU/ml penicillin and 0.1 mg/ml
streptomycin (Pen-Strep, Thermo Scientific) and 0.5 mM
valproic acid (VPA, SigmaAldrich), with subsequent media
change every alternate day up to 15 days. Well-grown dis-
tinct colonies were then individually picked by mechanical
passaging and transferred onto murine feeder cells (Global-
stem; GSC-6001) inactivated with mitomycin C (10 g/ml,
Santa Cruz Biotechnology) for further expansion and were
referred to as iPSC clones. At this stage, they were at pas-
sage 0 and maintained in culture till passage 13–14, before
these iPSC clones were characterized further for pluripo-
tency markers and teratoma formation (as described be-
low). These iPSC were subsequently cultured on feeder-
free Geltrex™ matrix (Thermo Scientific) and in Essential
8™medium (Thermo Scientific). Dulbecco’s phosphate buf-
ferred saline (DPBS) containing 50 mM EDTA (ethylene-
diamine-tetra-acetic acid, Thermo Scientific) was used to
detach the iPSC, which were then passaged at a split ratio
between 1:4 to 1:6.
Immunocytochemistry
The cells were washed with phosphate bufferred saline
(PBS) (Sigma Aldrich) and fixed with 4% paraformalde-
hyde (PFA; Sigma Aldrich) at room temperature (RT) for
10 min. Post-fixation cells were permeabilized with 0.2%
Triton X-100 (Sigma Aldrich) and 1% bovine serum albu-
min (BSA, Sigma Aldrich) in PBS for 15 min at room tem-
perature (RT). Donkey serum (10%) or goat serum (10%)
(Sigma Aldrich) was used to reduce potential background
to the secondary antibody. Cells were incubated overnight
at 4◦C with the following primary antibodies: mouse anti-
myosin heavy chain (MyHC; MF20, Developmental Stud-
ies Hybridoma Bank, USA; 1:2 dilution), mouse anti-lamin
A/C (Novocastra; NCL-LAM-A/C; 1:250 dilution), rabbit
anti-Sox2 (Abcam, USA; ab97959; 1:200 dilution), mouse
monoclonal anti-Oct3/4 (Santa Cruz Biotechnology, USA;
SC5279; 1:100 dilution), mouse monoclonal anti-spCas9
(Abcam, USA; ab210571; 1:200 dilution). After primary
antibody incubation, samples were washed with 0.2% Tri-
ton X100 (Sigma Aldrich) containing 1% BSA (Sigma
Aldrich) in PBS (Sigma Aldrich) and then incubated with
the corresponding 488, 594 and/or 647 nm fluorochrome
conjugated IgGs (Molecular Probes; 1:500 dilution) to-
gether with DAPI (Molecular Probes; 1:1000 dilution) for
1 h at RT in 0.2% Triton X100 in PBS. After three final
washes, dishes or slides were mounted using fluorescent
mounting medium (Dako) and observed under fluorescent
microscope (Leica, Olympus). Images were analyzed using
ImageJ (NIH) (https://imagej.nih.gov/ij/). To assess expres-
sion of alkaline phosphatase, the cells were washed with
PBS and fixed in 4% PFA (Sigma Aldrich) at RT for 10 min.
The cells were then stained with Sigma-Fast BCIP/NBT
staining kit (Sigma Aldrich; B5655–5TAB), as per manu-
facturer’s protocol.
Teratoma formation assay
All mouse experiments were carried out according to pro-
tocols approved by the university animal research ethical
committee of the Vrije Universiteit Brussel (VUB). For
teratoma formation, sub-confluent human iPSC were har-
vested and re-suspended in a 2:1 mixture of Essential 8™
medium (Life Technologies) andMatrigel (BDBiosciences)
with 10 MRho-associated, coiled-coil containing protein
kinase (ROCK) inhibitor (Y-27632, Stem cell Technolo-
gies). iPSC (106) were injected subcutaneously between the
shoulder blades of CB17 SCID mice (Taconic, Denmark).
The resulting tumors were harvested from the injected mice
8 to 9 weeks after transplantation. Samples were fixed in
10% neutral buffered formalin, embedded in paraffin and
sections were prepared for staining with hematoxylin and
eosin.
Array comparative genomic hybridization (aCGH)
Full human genome coverage aCGH was performed us-
ing a 180K Cytosure ISCA v2 array (Oxford Gene Tech-
nology, UK). It is based on 180K DNA oligonucleotides
spread over the genome with a minimal resolution of 100
kb and with a higher resolution at the loci for recog-
nized micro-deletions, micro-duplication syndromes, spe-
cific genes and the subtelomeric regions. Genomic DNA
from healthy donor iPSC and DM1-iPSC was extracted us-
ing Qiagen Blood &Tissue Kit (Qiagen, Germany) as per
manufacturer’s protocol. iPSC samples and commercially
available reference sample (EA-100F;Kreatech; theNether-
lands) were differentially labeled by random prime labeling
system using Cy3- and Cy5-labeled deoxycytidine triphos-
phates (dCTPs) (AmershamBiosciences). Post-labeling and
hybridization, slides were scanned using a high resolu-
tion microarray scanner (Agilent). aCGH analysis was per-
formed using CytoSure Interpret Software (Oxford Gene
Technology, UK).
Myogenic differentiation of iPSC
The differentiation protocol of DM1-derived or healthy
iPSC to muscle cells was based on our previously described
procedure (26,27). According to the four-stage differen-
tiation protocol (Supplementary Figure S4B), the iPSCs
were induced to differentiate into mesoangioblast-like cells,
which were designated as iPSC-Myo or DM1-iPSC-Myo
for the healthy and DM1-derived cells, respectively (iPSC-
Myo are equivalent to so-called HIDEMs or Human In-
duced pluripotent stem cell-DErived Mesoangioblast-like
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cells) (26). Each stage of the 4-stage protocol lasted 1 week
and required hypoxic culture conditions (3% O2). Firstly,
the healthy donor iPSCs or DM1-iPSCs were dissociated
into single cell suspension with an dissociation medium
containing 0.5 mM EDTA (Thermo Scientific), 0.1 mM
-mercaptoethanol (Thermo Scientific) and 1% FBS in
DPBS without CaCl2 and MgCl2 (Thermo Scientific) and
replated on Matrigel matrix (BD Biosciences) at a den-
sity of 3 × 105 cells/cm2 in -MEM nucleosides basal me-
dia (Thermo Scientific; Cat. No. 22571–020) containing
10% FBS (Thermo Scientific), 100 IU/ml penicillin and 0.1
mg/ml streptomycin (Pen-Strep, Thermo Scientific), 2 mM
L-glutamine and 0.1 mM -mercaptoethanol for 1 week at
37◦C, 5% CO2 and 2 to 3% O2. After one week of cul-
ture, the cells were again dissociated as in step 1 with gen-
tle scraping, if required. The cells were then replated on
Matrigel-coated surface at a density of 2.5 × 104 cells /cm2
in the same media as in stage 1. In the third stage, the
cells were trypsinized and replated on Matrigel at higher
cell density (∼2 × 104 cells/cm2 to obtain 80% confluency)
with iPSC-Myo medium composed of MegaCell medium
(Sigma Aldrich), 100 IU/ml penicillin and 0.1 mg/ml strep-
tomycin (Pen-Strep, Thermo Scientific), 5% FBS (Thermo
Scientific), 2mML-glutamine (Thermo Scientific), 1% (v/v)
MEM-Non Essential Amino Acid, 5 ng/ml basic fibrob-
last growth factor (bFGF, Thermo Scientific) and 0.05
mM -mercaptoethanol (Thermo Scientific). In the fourth
stage, cells were trypsinized and plated on uncoated sur-
face (withoutMatrigel) in iPSC-Myomedium and passaged
when confluent. From this stage, the iPSC-Myo cells ob-
tained were maintained like mesangioblast (Mabs) cells. Af-
ter the fourth stage, the cells were characterized for mem-
brane marker expression by flow cytometric analysis (as de-
scribed below). The final myogenic differentiation step in-
volved transducing the iPSC-Myo or DM1-iPSC-Myo with
a tamoxifen-inducible lentiviral vector expressing MyoD
(with multiplicity of infection, MOI = 20), as described in
Kimura et al. (33). Incubating the transduced cells with 1
mM tamoxifen (Sigma Aldrich) allowed for the inducible,
synchronous and efficient differentiation of the iPSC-Myo
and DM1-iPSC-Myo into mature, multinucleated skeletal
myotubes.
Flow cytometry
The cells were harvested as mentioned above and resus-
pended in PBS containing 1% FBS along with 0.5 mM
EDTA. The cell suspension was incubated with specific
antibodies for 1 h at 4◦C. The following monoclonal
antibodies were used: FITC (fluorescein isothiocyanate)-
conjugated anti-CD 13 (ID Labs, # IDAC1071), FITC-
conjugated anti-CD31 (Immunostep, # 31F-100T), FITC-
conjugated anti-CD44 (BD Biosciences, # 560977), FITC-
conjugated anti-CD 49b (BD Biosciences, # 555498), PE
(phycoerythrin)-conjugated anti-CD 45 (BD Biosciences, #
555483) and PE-conjugated anti-CD146 (Biocytex, # 5050-
PE100T). Thereafter, the cells were washed with PBS and
fixed in 2% PFA. Analysis was performed on at least 10,000
events per sample using a FACS caliber flow cytometer (BD
Biosciences). The acquisition was performed using CEL-
LQUEST software (BD Biosciences) and analyzed using
FCS-express software (DeNovo).
Southern blot analysis
GenomicDNAof healthy iPSCs, healthy iPSC-Myo, DM1-
iPSCs, DM1-iPSC clones and DM1-iPSC-Myo was ex-
tracted usingQiagenDNeasyBlood andTissue kit (Qiagen)
according to themanufacturer’s protocol. After digestion of
10 g DNA with EcoRI (Roche Diagnostics) and agarose
gel electrophoresis, the DNA was subjected to Southern
blot analysis using aDIG-labelled probe that was generated
with the PCR DIG Probe Synthesis Kit (Roche Diagnos-
tics). This probe was generated with forward primer 5′-TTA
TTGTCTGTCCCCACCTA-3′ and reverse primer 5′-G
GGATCACAGACCATTTCTTTCT-3′ specific to 3′UTR
region of human DMPK gene (Supplementary Figure
S4A).
Fluorescent in situ hybridization (FISH)
Healthy iPSCs or DM1-iPSCs were pre-treated with 10 M
Y-27632 rock inhibitor (RI, Stem cell Technologies) for 1
h prior to their dissociation with TrypLE Express (Life
Technologies). These cells were then plated on Geltrex (Life
Technologies)-coated chambered slides (LabTek) in Essen-
tial 8™ Medium (Life Technologies) containing Y-27632.
After overnight incubation, fresh Essential 8™ media was
provided without Y-27632. In the case of iPSC-Myo, DM1-
iPSC-Myo and DM1 primary myoblasts 0.05% trypsin-
EDTA (Thermo Scientific) was used to dissociate the cells
and plate them on 0.1% gelatin (Millipore)-coated cham-
bered slides (Thermo Scientific). On the day of staining, the
media was removed and cells were washed thrice with PBS
and fixed with 4% PFA (Sigma Aldrich) at RT for 15 min.
Thereafter, the cells were washed twice for 5 min each us-
ing 70% ethanol. After ethanol wash, the cells were rehy-
drated with two 10 min washes with 0.5 mMMgCl2 in PBS.
After the rehydration step, the cells were hybridized in a
hybridization chamber with custom Peptide Nucleic Acid
(PNA)-probe (CY3–5′-CAGCAGCAGCAGCAG-3′) (Eu-
rogentec) at a dilution of 1:500 in hybridization buffer [0.1%
BSA (Sigma Aldrich) in water, 50% volume of formamide
(Thermo Scientific) and 25% volume of SSC Buffer (Life
Technologies)] for 90 min at 37◦C. In the next step, the cells
were washed with 0.1% tween 20 (Sigma Aldrich) in PBS
for 5 min at RT. Thereafter the cells were incubated with
0.1% Tween 20 in PBS at 45◦C for 30 min. The incubation
was followed by three washes with PBS and DAPI staining
(Thermo Scientific) (1:500 dilution) for 7 min. After DAPI
staining, the slides were mounted using Prolong Anti-fade
mounting media (Thermo Scientific) and observed under
an inverted fluorescent microscope (Olympus). It is well es-
tablished that genomic DNA denaturation is critically im-
portant to enable efficient hybridization of the PNA FISH
probe to the DNA target (34–36). Hence, in the current
RNA FISH specific protocol we avoided any DNA denatu-
ration step following previously published reports, render-
ing any potentialDNA target inaccessible to the PNAFISH
probe (34–37).
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Combined FISH and immunofluorescence-specific for
the muscleblind protein 1 (MBNL1) was subsequently per-
formed according to Holt et al. (38). A monoclonal anti-
body specific for MBNL1 (# MB1a; CIND) (38) was used
as primary antibody at a dilution of 1:4 followed by Alexa
Fluor 647-conjugated donkey anti-mouse (Life Technolo-
gies) secondary antibody. After immunofluorescence, FISH
was performed as described above.Microscopy images were
captured using Nikon Eclipse 80i, Olympus-IX81 micro-
scope and Z stack acquisition was performed by Olympus-
IX81 microscope. Analysis of microscopy images was per-
formed by ImageJ software (NIH, https://imagej.nih.gov/
ij/).
CRISPR/Cas9 engineering of DM1-iPSC-Myo cells
The CMV-hspCas9-EF1-GFP lentiviral vector plas-
mid was purchased from System Biosciences (Catalog
# CASLV105PA-1) and expressed the human codon-
usage optimized S. pyogenes Cas9 from the human
cytomegalovirus (CMV) promoter (Supplementary Figure
S4C). It also expressed the green fluorescent protein
(GFP) as reporter from the elongation factor 1 promoter
(EF1α). The DNA encoding the 5′-CTGrepeat-gRNA and
3′-CTGrepeat-gRNA (Supplementary Table S1) were syn-
thesized as oligonucleotides, annealed and cloned into
MLM3636 (Addgene plasmid ID # 43860). The choice
of gRNAs was based on the presence of PAM consensus
sequences that were in close proximity to the expanded
CTG repeat. Moreover, gRNA were selected based on
computational strategies to also minimize the risk of
off-target effects, as described in Fu et al. (39,40). The
gRNA expression cassette composed of the pol III U6
promoter-gRNA-scaffold, which was then PCR-amplified
with BsiWI and SpeI flanking restriction enzyme sites and
cloned into a lentiviral vector backbone (41) along with
Blue fluorescent protein (BFP; Evrogen; FP172) a reporter
expressed under cytomegalovirus (CMV) promoter (Sup-
plementary Figures S4C and S5A). The scrambled gRNA
cassette was amplified from commercially available plasmid
(Origine, GE100021) and cloned into the lentiviral vector
backbone as described above.
Lentiviral transduction
Lentiviral transduction of the CMV-hSpCas9-EF1-GFP,
5′& 3′-CTGrepeat-gRNA-CMV-BFP and scrambled gRNA-
CMV-BFP was carried out with MOI = 25 per construct.
The lentiviral particles were produced as previously de-
scribed (42). A detailed protocol has beenmentioned in sup-
plementary methods. Transduction cocktail was prepared
using iPSC-Myo medium (see above) with polybrene (8
g/ml; Santa Cruz; sc134220) and the respective concen-
trated viral vector amount. The cells were incubated for 16
h with 7ml of the vector-containingmedium. Subsequently,
the medium was replaced with fresh iPSC-Myo medium.
Nucleofection and clonal isolation of DM1-iPSCs
The nucleofection of DM1-iPSCs were carried out using
Lonza P3 primary cell 4D nucleofection kit according to
manufacturer’s protocol (Lonza). Prior to nucleofection,
the DM1 –iPSCs were maintained in feeder free culture
condition as described previously. For the nucleofection re-
action mix, a ribonucleoprotein (RNP) complex was pre-
pared by mixing 60 pmol Cas9 protein (Integrated DNA
Technologies) and 150 pmol of each sgRNA (5′-CTGrepeat-
sgRNA, 3′-CTGrepeat-sgRNA) (Synthego) followed by a 10
min incubation at room temperature (control conditions
comprised the following: 60 pmol Cas9 and 300 pmol
scrambled gRNA; 150 pmol 5′-CTGrepeat-sgRNA, 150 pmol
3′-CTGrepeat-sgRNA and no Cas9) mixes. Thereafter, DM1–
iPSCs were dissociated into single cells with TrypLE ex-
press (Thermo Scientific). Post dissociation, 5 × 105 DM1–
iPSCs were resuspended in 20 l P3 nucleofection buffer
and mixed with previously prepared RNP complexes and
nucleofected using the ‘CA137’ program (using the Nucle-
ofector 4D). Post-nucleofection, the cells were plated on
geltrex-coated surface, in Essential 8™ medium (Thermo
Scientific) with 10M rock inhibitor (Y-27632, Stem cell
Technologies). A day post-nucleofection, cells were supple-
mented with fresh Essential 8™medium (Thermo Scientific)
and cultured for further downstream experiments. DM1–
iPSCs treated with Cas9 protein and sgRNA (5′-CTGrepeat-
sgRNA, 3′-CTGrepeat-sgRNA) were cloned by limiting dilu-
tion. Dissociated DM1–iPSCs were plated as single cells
on vitronectin (Stemcell Technologies) coated 96-well plate
with Clone R supplement and mTeSR culturing medium
(Stemcell Technologies). After 10–15 days of culturing with
regular media change, single clones were established. These
DM1-iPSC clones obtained were transferred to larger sur-
face area and maintained as iPSCs clonal lines until further
analysis.
qRT-PCR and RT-PCR analysis
RNA was extracted using Qiagen RNeasy Mini kit (Qi-
agen) according to manufacturer’s instruction. The ex-
tracted RNA was used for cDNA synthesis using Super-
script III-RT cDNA synthesis Kit (Life technologies) ac-
cording to manufacturer’s protocol. 1g RNA was taken
as starting amount for the cDNA synthesis. Upon cDNA
synthesis, it was stored at −20◦C until used for quanti-
tative reverse transcription (qRT)-PCR. qRT-PCR anal-
ysis for DMPK expression was performed using SYBR
green (Thermo Scientific) with specific primers for DMPK
(5′- GGATGAAACAGCTGAAGTGGC -3′ and 5′- TGCC
TCTAGGTCCCGGTTC -3′) and hGAPDH housekeeping
gene (5′-GAAGGTGAAGGTCGGAGTC-3′ and 5′-GAA
GATGGTGATGGGATTTC-3′) as control for normaliza-
tion. For the analysis of the alternative-splicing patterns
of SERCA1 mRNA, 1 g of extracted mRNA was reverse
transcribed to cDNA using Superscript III-RT cDNA syn-
thesis Kit (Thermo Scientific). The synthesized cDNA was
diluted 1:5 with nuclease-free H2O and used for RT-PCR.
PCR mix consisted of 2 l of diluted cDNA, 0.2 l Phu-
sion Hot Start II DNA Polymerase (Thermo Scientific), 0.4
l 10 mM dNTP Mix (Thermo Scientific), 4 l 5x Phusion
GCBuffer (ThermoScientific), 2l each of 5MSERCA1-
specific forward primer 5′-GCTCATGGTCCTCAAGATC
TCAC-3′ and reverse primer 5′-AGCTCTGCCTGAAGA
TGTGTCAC-3′. PCR amplification was performed by an
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initial denaturation for 2 min at 98◦C; followed by 25–35
cycles consisting of 10 s at 98◦C, 30 s at an annealing tem-
perature of 59◦C and 30 s at 72◦C which was then con-
cluded by a final extension of 2 min at 72◦C. PCR reac-
tions were performed using an s1000 Thermal Cycler (Bio-
Rad). PCR amplicons were electrophoretically resolved on
3% agarose gels containing EtBr and visualized by an Al-
pha Imager HP (Cell Biosciences). The band-density was
quantified using ImageJ software analysis tool (NIH, https:
//imagej.nih.gov/ij/) as described in previously published re-
ports (43–45). A detailed analysis procedure is mentioned
in Supplementary Methods section.
Triplet repeat Primed PCR (TP-PCR)
Triplet-repeat primed PCR was performed as described
in Philippa et al. (46). Each 25 l PCR comprised Fast-
Start Reaction Buffer without MgCl2 (Roche), 2 mM
MgCl2 (Roche), GC-rich solution (Roche), 10 mM
dNTP mix (Roche), 20 M forward primer (FAM)
5′-AACGGGGCTCGAAGGGTCCTTGTAGC-3′ and
reverse primer 5′-GGCGGTGGCGGCTGTTGCCAGCA
GCAGCAGCAG-3′, 1U FastStart Taq DNA Polymerase
(Roche) and 50 ng of genomic DNA. The PCR amplifi-
cation conditions comprised of an initial denaturation of
94◦C for 5 min followed by 35 cycles of denaturation at
94◦C for 45 s, annealing at 70◦C for 30 s with extension at
72◦C for 30 s and a final extension at 72◦C for 10 min. PCR
amplicons were subjected to fragment length analysis by
capillary electrophoresis on an Applied Biosystems DNA-
Analyzer (ABI 3730) with ROX as internal size marker. The
data was analyzed using Peak-Scanner software (Thermo
Scientific).
Single-molecule real-time (SMRT) sequencing of the target
locus
Genomic DNA of CRISPR/Cas9-corrected DM1-iPSC-
Myo, untreated DM1-iPSC-Myo, non-corrected DM1-
iPSC-Myo control conditions (i.e. Cas9 and scrambled
gRNA; 5′-CTGrepeat-gRNA, 3′-CTGrepeat-gRNA and no
Cas9) and wild-type iPSC-Myo was extracted using Qia-
gen DNeasy Blood and Tissue kit (Qiagen) according to
themanufacturer’s protocol.GenomicDNA (20–40 ng)was
used for PCR. The target locus was amplified using the
LongAmp Taq PCR kit (New England Biosciences) based
on the 5′-ATCTTCGGGCAGCCAATCAAC-3′ (DM-PAC,
forward primer) and 5′-CGTGGAGGATGGAACACGGAC
-3′ (DM-BR, reverse primer) that match a target sequence
571 basepair (bp) upstream and 62 bp downstream of the
respective CRISPR/Cas9 PAM target sites flanking the
DMPK CTG repeat (Figure S6A) PCR amplification was
performed by an initial denaturation for 2 min at 94◦C,
followed by 30 cycles consisting of 30 s at 94◦C, 30 s at
the 60◦C, prolonged 8 min extension at 65◦C and con-
cluded by a final extension of 10 min at 65◦C. PCR re-
actions were performed using an s1000 Thermal Cycler
(Bio-Rad). Thereafter, library preparation of the ampli-
cons was carried out using PacBio Barcoded Adapters for
Multiplex SMRT Sequencing using SMRT bell Barcoded
Adapter Complete Prep Kit (Pacific Biosciences, Menlo
Park, CA, USA). During the library preparation each am-
plicon was labeled with a different barcode, which was in-
troduced via the PacBio adapter. Each library was sub-
sequently sequenced on a PacBio RS II sequencer us-
ing the DNA/polymerase binding Kit P6 v2 (Pacific Bio-
sciences) for a 360-min movie. All sequencing runs used
PacBio’sDNASequencing reagentKit 4.0 v2. Post sequenc-
ing the long reads generated by SMRT sequencing cross
each molecule multiple times generating highly accurate
reads. Demultiplexed Circular Consensus (CCS) reads were
therefore generated with the RS ReadsOfInsert.1 protocol
from the PacBio’s SMRT portal (v2.3.0) with a minimum
of one full pass, a minimum predicted accuracy of 90% and
demultiplexing with symmetric barcodes. Afterwards a cus-
tom python script was used to extract the input read size of
on-target reads and to determine the size and structure of
the repeat when present in the read.
On-target and off-target analysis by DNA sequencing
The CRISPR/Cas9-targeted locus was subjected to Sanger
sequencing. The target locus was amplified using 5′-
CTGGTCTCCCCGTCCAGATA-3′ (forward primer) and
5′-GAACCAACGATAGGTGGGGG-3′ (reverse primer).
PCR amplification was performed by an initial denatura-
tion for 2 min at 98◦C; followed by 35 cycles consisting of
10 s at 98◦C, 30 s at the 59◦C, 30 s at 72◦C and concluded
by a final extension of 8 min at 72◦C. PCR reactions
were performed using an s1000 Thermal Cycler (Bio-
Rad). PCR products were cloned into Zero Blunt TOPO
vector (K2875-J10, Life Technologies) and transformed
into bacteria. Plasmids containing PCR amplicon in-
serts were extracted using the plasmid mini-prep system
(Promega) and sequenced using a T3 sequencing primer
(5′-ATTAACCCTCACTAAAGGGA–3′) by the Sanger se-
quencing (GATC, Germany). The sequences were analyzed
using Ape software (http://biologylabs.utah.edu).
Off-target sites for the 5′-CTGrepeat-gRNA and 3′-
CTGrepeat-gRNA (Supplementary Table S2), were predicted
using the validated algorithm from the Zhang lab (http:
//crispr.mit.edu/). From the list of 20 predicted off-target
sites identified by this algorithm, we selected the four most
probable off-target sites for the 5′-CTGrepeat-gRNA and 3′-
CTGrepeat-gRNA, that shared significant homology with the
actual on-target sites (Supplementary Table S2). These se-
lected off-target sites were PCR-amplified and were sub-
jected to deep sequencing. Briefly, PCR amplification was
performed by an initial denaturation for 2 min at 98◦C;
followed by 35 cycles consisting of 10 s at 98◦C, 30 s at
the 58◦C, 30 s at 72◦C and concluded by a final extension
of 8 min at 72◦C using Phusion Hot Start II high-fidelity
DNA polymerase (F549S; Life Technologies) and the re-
spective primers (Supplementary Table S3) to generate PCR
products of sizes 226–387 bp. After PCR and agarose gel
electrophoresis, the PCR products were purified using QI-
Aquick Gel Extraction Kit (Qiagen). The PCR products
were sequenced and analyzed using the MiSeq PE150 plat-
form (BGI, Europe). Raw image files were processed by Illu-
mina pipeline for base calling with default parameters and
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the sequences of each individual sample were generated as
150-bp paired-end reads. The 150-bp paired end reads were
subjected to bioinformatics analysis.
The raw data were quality controlled by removing the Il-
lumina adapter sequences and low quality reads were dis-
carded using SOAP (Short Oligonucleotide Alignment Pro-
gram; BGI, Hongkong). Subsequently, the read data were
aligned to the human reference genome sequence (Homo
sapiens GRCh38/hg38) using Burrows-Wheeler Aligner
(BWA) in the Biostar Galaxy (http://usegalaxy.org) result-
ing in BAM format files. The BAM files were imported
into Geneious R9.1.2 (Biomatters Ltd, New Zealand) to
visualize the alignment of reads on human chromosomes.
The analysis of small insertions and deletions (indels) was
performed using FreeBayes variation/SNP analysis [(Gar-
rison E, M.G. 2012) Haplotype-based variant detection
from short-read sequencing. arXiv.org. arXiv:1207.3907 [q-
bio.GN]], which is the Bayesian genetic variant detector
designed to find small polymorphisms. The percentage of
insertions/deletions (indels) were obtained by polymor-
phisms with the following parameters: mapping quality, al-
ternate allele frequency, ploidy of 2, minimum alternate
count of 2,minimumalternate fraction of 0.2, and combines
nearby variants of 3. Afterward, the annotation of polymor-
phism was also generated as vcf files and the data were ex-
ported as CSV format. The % InDels of the nucleotide po-
sition around PAM sequence were plotted using GraphPad
Prism 6 (GraphPad Software Inc., USA).
Study design
The data sets were based on three independent
CRISPR/Cas9-based correction experiments in four
different DM1-iPSC-derived myogenic cell cultures. The
data are based on a total of four DM1-iPSC cell lines from
two DM1 patients and their respective DM1-iPSC-Myo
derivatives. Each correction experiment was independently
performed at a separate time point (n = 3). Quantification
of the nuclear foci was performed in a blinded fashion.
Consequently, all of the downstream experiments were
also repeated accordingly, based on these independently
generated DM1-iPSC-Myo cells. In particular, this implies
that the nuclear foci quantification, SERCA1 splicing anal-
ysis, MBNL co-localization, DMPK mRNA expression
analysis were based on four DM1-IPSC-Myo cultures (des-
ignated as L23, L81 from DM1 patient #1; FL5, FL8 from
DM1 patient #2) and three independent CRISPR/Cas9
correction experiments (total n = 12). The cells used in this
study are of human origin which was authenticated with
aCGH for genomic integrity. The cultures were negative
for mycoplasma. Statistical methods such as unpaired
Student’s t-test and one-way ANOVA were performed as
indicated with statistical significance level () set at 0.05:
*P < 0.05, **P < 0.01, ***P < 0.001. Ribonuclear foci
were quantified either by manual multifocal acquisition or
by a z-stack acquisition method, as specified accordingly.
Bland–Altman statistical plot confirmed that the two
methodologies were in agreement and could be considered
interchangeable.
RESULTS
Characterization and myogenic differentiation of DM1
patient-specific induced pluripotent stem cells (DM1-iPSCs)
Both primarymyoblasts and fibroblasts fromDM1 patients
were reprogrammed into iPSCs (designated as DM1-iPSCs)
by retroviral transduction of four reprogramming factors
OCT4, SOX2, KLF and c-MYC (32). Mouse embryonic fi-
broblasts (MEFs) were briefly used as feeder cells during the
generation of iPSCs. The individual DM1-iPSC clones (des-
ignated as L22, L23, L81; patient #1; FL8, FL5; patient #2)
were subsequently expanded in feeder-free conditions (Sup-
plementary Figures S1A and S3A). The pluripotency of the
DM1-iPSC clones was ascertained by assessing the pluripo-
tency maker expression, i.e. OCT4, SSEA4, SSEA3, TRA
1–60 and alkaline phosphatase (AP) (Supplementary Fig-
ure S1B) and by demonstrating their ability to generate ter-
atomas consisting of ectoderm, endoderm and mesoderm
tissue structures after subcutaneous transplantation into
CB17 SCID mice (Supplementary Figure S1D). Similarly,
the pluripotency was also confirmed for DM1-iPSC clones
FL5 and FL8 (patient #2). Molecular karyotyping of the
newly generated DM1-iPSC clones (L22, L23, L81; FL8,
FL5) by array comparative genome hybridization (aCGH)
with a 100 kb resolution revealed a normal karyotype (Sup-
plementary Figures S1C and S3C).
The CTG trinucleotide repeat expansion was confirmed
by Southern blot analysis of the DMPK locus with a probe
specific for the DMPK 3′ UTR region (Figure 1C; Supple-
mentary Figure S4A). Southern blot analysis revealed that
the DM1-iPSC clones were heterozygous and contained a
mutated DMPK allele with a characteristic CTG repeat ex-
pansion and a wild-type DMPK allele. CTG trinucleotide
repeat expansion in the DM1-iPSC clones derived from pa-
tient #1 (L22 and L23) corresponded to ∼1000 and ∼1300,
respectively, whereas clone L81 exhibited two expanded
populations having ∼1400 and ∼1600 repeats (Figure 1C).
Triplet-repeat length in theDM1-iPSCs FL8 clone from pa-
tient #2was∼1700, whereas theFL5 clone exhibited two re-
peat sizes corresponding to ∼1400 and ∼1600 repeats (Fig-
ure 1C). The difference in repeat length among the different
DM1-iPSC clones derived from the same patientmay reflect
somatic mosaicism in the original DM1 patient-derived pri-
mary cells from which the iPSCs were derived consistent
with somaticCTG instability (47). This is in line with the oc-
currence of somatic CTG repeat instability in DM1 mouse
models in vivo. However, it cannot be excluded that this
CTG repeat instabilitymay arise upon cell expansion in vitro
(48–51).
Analysis of our Southern blots for the healthy control iP-
SCs show two bands ∼1 kb apart (Figure 1C, Supplemen-
tary Figure S4A). The experimental observation (in Figure
1C) is in agreement with knownAlu polymorphisms seen in
the DMPK locus (4,52,53). Therefore, considering our ob-
servation and the previous studies (4,52,53), we could infer
that the two distinct bands for the healthy control DMPK
alleles represent two polymorphic DMPK alleles. The up-
per band of the healthy control iPSC contain the ∼1 kb
Alu repeat (designated as Alu+) whereas the lower band did
not (designated as Alu-). Southern blot analysis revealed
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Figure 1. Generation ofDM1-iPS cells (DM1-iPSCs) andDM1-iPSC derived inducible myogenic cells (DM1-iPSC-Myo). (A) Schematic overview showing
CRISPR/Cas9 based correction of DM1 patient iPSCs derived myogenic cells (DM1-iPSC-Myo). (B) Representative image of DM1-iPSC clones and
healthy control iPSCs stained for RNA foci by fluorescent in situ hybridization (FISH). An antisense Cy3-labeled probe was used against trinucleotide
CUG expanded repeat. Arrowheads indicated ribonuclear foci. Upper panel represents stained nuclei at lower magnification (scale bar = 20m) and lower
panel represents higher magnification of selected region (scale bar = 2m). Nuclei were counter-stained with DAPI. (C) Southern blot analysis to detect
the length of trinucleotide CTG repeats in five DM1-iPSC clones from two DM1 patients (L22, L81 and L23; FL8 and FL5) and healthy control iPSCs.
EcoRI digested genomic DNA was subjected to agarose gel electrophoresis and probed to detect the DMPK locus. (mut = mutant; wt = wild type). (D)
Representative image of FISH staining on DM1-iPSC-Myo for detection of ribonuclear foci. Arrowheads indicate multiple RNA foci in nuclei of DM1-
iPSC-Myo. Healthy iPSC-Myo were used as a negative control. Upper panel represents stained nuclei at lower magnification (scale bar = 20 m) and
lower panel represents higher magnification of selected region (scale bar = 2 m). Nuclei were counter-stained with DAPI. (E) Myogenic conversion of
DM1-iPSC-Myo (L81 and L23) and healthy iPSC-Myo postMyoD induction were stained for a mature muscle marker, myosin heavy chain (MyHC) (scale
bar = 100 m). Nuclei were counter-stained with DAPI. (F) Southern blot analysis of trinucleotide CTG repeats length in DM1-iPSC-Myo (L81 and L23;
FL8 and FL5) and healthy-iPSC-Myo to check the length of triplet repeats post-differentiation (mut = mutant; wt = wild type).
that the wild-type DMPK allele of the DM1-iPSC clones
L81 and L23 is Alu+ (Figure 1C and Supplementary Fig-
ure S4A), whereas the wild-type DMPK allele of the DM1-
iPSC clones FL8 and FL5 is Alu- (Figure 1C and Supple-
mentary Figure S4A). Subsequent sequencing confirmed
that the wild-type DMPK allele contained a normal num-
ber of CTG repeats (patient #1: 5 CTG repeats; patient #2:
13 CTG repeats) (Supplementary Figures S7A and B).
One of the hallmarks of DM1 is the emergence of ribonu-
clear foci in the nuclei of the affected patient cells, due to
the expanded CUG repeats in the 3′UTR region of DMPK
transcript (54). We therefore confirmed the presence of the
ribonuclear foci in the DM1-iPSC clones by fluorescence in
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situ hybridization (FISH) (Figure 1B, Supplementary Fig-
ure S3D). The number of ribonuclear foci in DM1-iPSCs
typically ranged from three to five per nucleus with a max-
imum of eight to nine foci per nucleus. As expected, no ri-
bonuclear foci were detected in the iPSCs derived from a
healthy donor (Figure 1B).
Since DM1 patients suffer from muscle dysfunction, we
subsequently induced the DM1-iPSCs to differentiate into
myogenic cells using an established myogenic differentia-
tion protocol (Supplementary Figure S4B), we have pre-
viously reported (26,27). As expected the four-stage differ-
entiation process yielded a population of iPSC-derived in-
duced myogenic cells (designated as DM1-iPSC-Myo) hav-
ing robust in vitro expansion potential (Supplementary Fig-
ures S1E and S3A). Cytofluorimetric analysis of the DM1-
iPSC-Myo revealed expression ofmesodermal/vascular cell
surface markers such as CD13, CD44, CD49b and CD146
but absence of CD31 and CD45 (Supplementary Figure
S2A). The DM1-iPSC-Myo also displayed alkaline phos-
phatase (AP) expression, detectable using enzymatic activ-
ity assays (Supplementary Figure S2C). Importantly, apart
from being a marker of pluripotent stem cells, AP is also
a characteristic marker of DM1-iPSC-Myo cells (26,27),
since they are similar to AP-positive mesoangioblasts (29).
The expression of thesemarkers onDM1-iPSC-Myo is con-
sistent with the expression pattern on both normal healthy
iPSC-Myo and primary human skeletal muscle pericyte-
derived mesoangioblasts (Supplementary Figures S2C and
A) (26,27) (29). The differentiation of DM1-iPSCs into
DM1-iPSC-Myo (or control healthy iPSCs into iPSC-Myo)
was relatively robust, as we could not detect presence of any
residual undifferentiated OCT4+ or SOX2+ DM1-iPSCs
(Supplementary Figure S2B). The DM1-iPSC-Myo and
control iPSC-Myo were stained for human lamin A/C and
the analysis of staining showed uniform positive expression
of human lamin A/C in these differentiated cells. We could
not detect any human Lamin A/C negative residual murine
feeder cells that were employed during the initial stages of
iPSCs generation (Supplementary Figure S1F).
Subsequently, we analyzed the expanded CTG repeat
length in the DM1-iPSC-Myo cells upon myogenic differ-
entiation of the DM1-iPSC clones. Triplet-repeat length in
DM1-iPSC-Myo L23 was ∼1300, whereas L81 had two ex-
panded populations having ∼1200 and ∼1400 repeats. This
is consistent with the repeat length in the respective original
DM1-iPSC clones derived from patient #1. In the second
DM1 patient, the DM1-iPSC-Myo FL5 population con-
tained ∼1400 and ∼1600 repeats (Figure 1F). This is also
in accordance with the number of repeats in the original
DM1-iPSC clone from patient #2. However, a slight reduc-
tion in repeat length was apparent in the FL8 population,
compared to the original DM1-iPSC clone (i.e. ∼1500 ver-
sus ∼1700) (Figure 1C and F). This could possibly be at-
tributed to CTG repeat instability upon cell expansion in
vitro as reported in previous studies (48–51). In contrast,
the control healthy iPSC-Myo showed the expected pattern
of 5CTG repeats as in their iPSCs counterparts, fromwhich
they were derived (Figure 1F).
Most importantly, the presence of CTG repeats in the
DMPK 3′ UTR was consistent with the emergence of
the characteristic ribonuclear foci in the DM1-iPSC-Myo,
whereas no foci could be detected in control healthy iPSC-
Myo (Figure 1D). It is noteworthy that these ribonuclear
foci were larger and brighter in the DM1-iPSC-Myo than
in the undifferentiatedDM1-iPSCs, in accordance with pre-
vious studies (55). Finally, to complete the myogenic dif-
ferentiation process, we subjected the DM1-iPSC-Myo to
MyoD-induced myogenic differentiation into skeletal my-
otubes and myocytes, as described previously (26,27). The
widespread expression of myosin heavy chain (MyHC),
a mature muscle marker, in the differentiated multinucle-
ated myotubes was consistent with robust differentiation
of DM1-iPSC-Myo (or healthy control iPSC-Myo) with
>80% efficiency (Figure 1E, Supplementary Figure S3B).
Hence, a patient-specific DM1-iPSC-derived cellular model
was hereby established capable of robust myogenic differen-
tiation into DM1-patient specific mesoangioblast-like cells,
myocytes and myotubes. Hence, this served as a suitable
DM1 in vitro disease model to further examine the conse-
quences of CRISPR/Cas9-mediated excision of the CTG
repeats in the mutant DMPK allele.
CRISPR/Cas9-mediated targeting of CTG trinucleotide re-
peats in DM1-iPSC-derived myogenic cells
The validation of the myogenic DM1-iPSC-Myo cellular
platform allowed us to subsequently assess the potential of
CRISPR/Cas9 to specifically excise the CTG trinucleotide
repeats. We therefore generated lentiviral vectors that ex-
pressed the S. pyogenesCas9 protein and a green fluorescent
protein (GFP) reporter gene (Supplementary Figure S3C).
In addition, lentiviral vectors that expressed gRNAs specifi-
cally designed to target sequences just 5′ upstream and 3′
downstream of the CTG repeat expansion in the DMPK
3′UTR (designated as 5′-CTGrepeat-gRNA and 3′-CTGrepeat-
gRNA) along with a blue fluorescent reporter (BFP) gene
were produced (Figure 2A, Supplementary Figures S5A
and B). As controls, we used vectors that were identical
in design but encoded scrambled gRNAs instead. Fluores-
cence microscopy analysis and quantification of GFP+ and
BFP+ DM1-iPSC-Myo at 72 h post transduction revealed
relatively robust transduction efficiency corresponding to
84 ± 5% for Cas9 (GFP) and 93 ± 6% for both gRNAs
combined (i.e. 5′-CTGrepeat-gRNA and 3′-CTGrepeat-gRNA)
(BFP) (Supplementary Figures S5A and B). To directly as-
sess the Cas9 protein expression in DM1-iPSC-Myo cells
transduced with the Cas9 vector an immunofluorescence
staining was performed using Cas9-specific monoclonal an-
tibodies. A total of 82.7± 3.2% to 91.0± 0.3% of the trans-
duced DM1-iPSC-Myo cells (derived from three indepen-
dent DM1-iPSC clones L23, FL8 and FL5) expressed the
Cas9 protein (average: 85.1 ± 4.5%) (Figure 2B; Supple-
mentary Figure S5C). This is consistent with the assessment
of transduction efficiency based on GFP expression (Sup-
plementary Figures S5A and B). These results indicated
that most cells expressed Cas9 and that the transduction ef-
ficiency and expression of the Cas9 was relatively robust.
Nevertheless, some variation in fluorescence intensity was
apparent, indicating that Cas9 expression did vary among
individual cells.
To assess whether CRISPR/Cas9 can be used to excise
the CTG repeats in DM1 patient’s cells, a rapid triplet re-
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Figure 2. A dual gRNA approach for CRISPR/Cas9-mediated correction of DM1-iPSC Myo and evidence for trinucleotide CTG repeat excision. (A)
Diagrammatic representation for targeting of the 3 ‘UTR region of the DMPK gene using a dual gRNA approach for CRISPR/Cas9-mediated gene
correction. The dual gRNAs (5′& 3′-CTGrepeat-gRNA) target Cas9 on either side of theCTG repeat region for excision of the expanded trinucleotide repeat.
(B) Cas9 immunofluorescence staining of CRISPR/Cas9 treated DM1-iPSC-Myo cells, at 1-week post transduction. The upper panel shows representative
images of DM1-iPSC-Myo cells stained for Cas9 (in red) and co-stained with DAPI for nuclei (in blue) (scale bar = 50 m). The lower panel shows the
graph for the quantitation of microscopy data for Cas9 positive cells. (C) Representative electropherograms of Triplet Repeat Primed PCR (TP) products
from DM1-iPSC-Myo after CRISPR/Cas9-mediated gene editing from three independent experiments for each of the three treatments (Cas9 and 5′ & 3′-
CTGrepeat-gRNA; Cas9 and scrambled gRNA; 5′-CTGrepeat-gRNA, 3′-CTGrepeat-gRNA and no Cas9) and untreated control conditions (WT-iPSC-Myo
and DM1-iPSC-Myo). (D) Sanger sequencing results of on-target activity. The DMPK target locus was amplified by primers flanking the 2 SNPs [C>T;
G>A: mutant > wild-type allele] and the CTG repeat region [(CTG)∼1371 /(CTG)5]. The SNPs allowed discrimination of mutant (C&G) and wild-type
alleles (T&A). Analysis of CRISPR/Cas9 activity on the targeted mutant allele showed a large deletion [(–) ∼4188 bp] between the 5′-CTGrepeat-gRNA
and 3′-CTGrepeat-gRNA target sites. CRISPR/Cas9 activity on wild type allele was also detected by deletions between the corresponding gRNA target
sites. Representative sequences of the wild-type allele with commonly found deletions and insertions are depicted in the figure. SNPs marked in red are
seen in the mutant allele and those in blue are present in the wild type allele. Insertions are indicated by (+) and deletions are indicated by (–). Small letters
represent the inserted nucleotides.
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peat primed PCR (TP-PCR) assay was conducted on the
genomicDNA isolated from the CRISPR/Cas9 transduced
DM1-iPSC-Myo (Figure 2C) (13). Capillary electrophore-
sis of the PCRamplicons and analysis of the pattern of PCR
amplicons revealed a pronounced difference in the signal in-
tensity in the CRISPR/Cas9-treated cells compared to con-
trols. In particular, DM1-iPSC-Myo engineered with Cas9
and the 5′-CTGrepeat-gRNA and 3′-CTGrepeat-gRNA exhib-
ited a marked decrease in the frequency (signal intensity)
of PCR amplicons compared to control DM1-iPSC-Myo
cells transduced with Cas9 and the scrambled gRNA or only
with the 5′-CTGrepeat-gRNA and 3′-CTGrepeat-gRNA with-
out Cas9. The disappearance of the characteristic CTG re-
peat pattern after gene editing with Cas9 and the dual 5′-
CTGrepeat-gRNA and 3′-CTGrepeat-gRNA resemble that of
healthy control iPSC-Myo and was consistent with the re-
moval ofCTG repeats in theDMPK3′UTR. Conversely, the
CTG repeat pattern of the control conditions either without
Cas9 or with scrambled gRNAs (and Cas9) resembled that
of non-transduced DM1-iPSC-Myo control cells, indicat-
ing that theCTG repeats remained intact within theDMPK
3′ UTR locus for those control conditions. Taken together,
these findings strongly suggested that treating DM1-iPSC-
Myo with CRISPR/Cas9 resulted in a relatively robust ex-
cision of the CTG repeats from the DMPK 3′ UTR. This
obviated the need for selective enrichment of gene-edited
cells subsequent toCRISPR/Cas9 correction. The TP-PCR
analysis supported the hypothesis that the expanded CTG
repeat was excised by the CRISPR/Cas9 system in the
DM1-iPSC-Myo cells.
Subsequently, we demonstrated by Sanger sequencing of
the junction area post-excision, that the CTG repeat of
both wild-type and mutant DMPK alleles could be excised
by CRISPR/Cas9. We therefore exploited the presence of
single nucleotide polymorphisms (SNPs) in the wild-type
DMPK allele which is distinct from the mutant DMPK al-
lele. The DM1 patient’s cells were heterozygous with re-
spect to the CTG repeats in the DMPK 3′UTR yielding
>1000 repeats in the mutant allele and only 5 CTG re-
peats in the wild-type allele (Figure 1C–F and Supplemen-
tary Figure S4A). In addition, we identified two small nu-
cleotide polymorphisms (SNPs) further distinguishing this
mutant from the normal allele. The corresponding T→C
and A→G SNPs were located respectively at position 835
and 640 nucleotides upstream from the 5′ end of the CTG
repeat (Figure 2D). The presence of these two SNPs was ex-
ploited to independently confirm excision of the expanded
CTG repeats by Sanger sequencing on amplicons, ampli-
fied by primers flanking the SNPs and the expanded CTG
repeats (Figure 2D). Deletion of ∼ 4188 bp fragment re-
sulted in the excision of the entire full-lengthCTG repeat ex-
pansion in the CRISPR/Cas9-corrected DM1-iPSC-Myo.
This deletion was flanked by the respective 5′-CTGrepeat-
gRNA and 3′-CTGrepeat-gRNA target sites and was consis-
tent with the requirement of a protospacer adjacent motif
(PAM) near the Cas9 cleavage site. Taken together, these
results confirm the TP-PCR data (Figure 2C) and demon-
strate CRISPR/Cas9-mediated editing of the CTG trinu-
cleotide repeat expansion in DM1-derived myogenic cells.
The presence of the SNPs further distinguished wild-type
from mutant DMPK alleles also permitted the identifica-
tion of deletions of the (CTG)5 repeat region and small
insertions/deletions (indels) at the 5′-CTGrepeat-gRNA and
3′-CTGrepeat-gRNA target sites in the wild-type DMPK lo-
cus. Since the 5′-CTGrepeat-gRNA and 3′-CTGrepeat-gRNA
target sites were located in the 3′ UTR of the DMPK gene,
this design avoids altering the DMPK protein-coding se-
quence itself. Although due to the design of the gRNAs that
targeted a sequence in proximity of the PAMconsensus sites
upstream and downstream of the CTG repeat, some flank-
ing non-repeat sequences were also excised, as expected.
To better characterize the molecular consequences of the
CRISPR/Cas9-mediated excision of the CTG repeat, an
emerging new sequencing technology was employed based
on single-molecule real time (SMRT) sequencing, given its
high accuracy and ability to sequence even through ex-
tended trinucleotide repeat regions (56,57). Prior to SMRT
library preparation and sequencing, the 3′ UTR DMPK
target region of the CRISPR/Cas9-corrected DM1-iPSC-
Myo, untreated DM1-iPSC-Myo and non-corrected DM1-
iPSC-Myo control conditions (i.e. Cas9 and scrambled
gRNA; 5′-CTGrepeat-gRNA, 3′-CTGrepeat-gRNA and no
Cas9) was PCR-amplified (Figure 3A–C, Supplementary
Figure S6A and B). The amplicons were subsequently an-
alyzed by gel electrophoresis. In the case of the non-edited
control cells (i.e. untreated DM1-iPSC-Myo, non-corrected
DM1-iPSC-Myo cells), we expected two different sizes of
the amplified products; a ∼ 723 bp amplicon from the un-
cut wild-type DMPK allele and a >4000 bp amplicon from
the uncut mutant DMPK allele containing the CTG repeat
expansion (Figure 3A, Supplementary Figure S6A and B).
Similarly, the wild-type iPSC-Myo cells yielded only the
∼723 bp amplicon.
The CRISPR/Cas9-treated DM1-iPSC-Myo cells con-
tained a mixed population of both edited and non-edited
cells, consistent with the nuclear foci results (Figure 3B–D;
Supplementary Figures S8A–C) Complete excision of the
CTG repeat expansion, along with the flanking sequences
containing the PAM consensus sites, resulted in an ampli-
fied product of ∼633 bp. This ∼633 bp amplicon corre-
sponded to both wild type and mutatedDMPK alleles from
the DM1-iPSC-Myo cells subjected to CRISPR/Cas9-
mediated editing with Cas9 and 5′ & 3′-CTGrepeat-gRNAs
(Figure 3A, Supplementary Figure S6A and B). In contrast,
this 633 bp amplicon was absent in all of the control condi-
tions (i.e. untreatedDM1-iPSC-Myo cells, DM1-iPSC-Myo
cells treated with Cas9 and scrambled gRNA; DM1-iPSC-
Myo cells treated with 5′-CTGrepeat-gRNA, 3′-CTGrepeat-
gRNA and no Cas9). Since the CRISPR/Cas9-treated
DM1-iPSC-Myo cell population also contained unedited
cells, we could detect the ∼723 bp amplicon correspond-
ing to the unedited wild-type allele. Interestingly, the DM1-
iPSC-Myo cells subjected to CRISPR/Cas9-mediated edit-
ing with Cas9 and 5′&3′-CTGrepeat-gRNAs did not only
show the expected∼633 bp amplicon but also displayed am-
plicons with varying sizes that fell in the range of 723–4000
bp. The occurrence of such a heterogeneous amplicon pat-
tern would be consistent with a partial deletion of the CTG
repeats at either the 5′ or 3′ end of the repeat expansion.
This could be explained by a single gRNA-mediated Cas9
cleavage either upstream or downstream of the CTG repeat
expansion in the 3′ DMPKUTR. This is consistent with the
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Figure 3. Analysis of target region in the CRISPR/Cas9-corrected DM1-iPSC-Myo and ribonuclear foci staining of corrected DM1-iPSC-Myo and DM1
primary myoblasts. (A) Graph representing distribution of SMRT sequencing reads based on the various amplicon sizes ∼633 bp (excised fragments) and
∼723bp (WT fragments). The sequences ranging between∼723 bp and∼4000 bp were fragments with indels and partially deleted repeat regions. Each bar
represents distribution of reads from each of the three conditions (Cas9 + 5′ & 3′-CTGrepeat-gRNA, Cas9 control and gRNA control) and untreated DM1-
iPSC-Myo control. (B) Representative image of CRISPR/Cas9-corrected DM1-iPSC-Myo (L81) stained for ribonuclear foci. Cas9 and scrambled gRNA;
5′-CTGrepeat-gRNA, 3′-CTGrepeat-gRNA and no Cas9 were used as negative controls. An antisense Cy3-labeled probe was used to detect the presence of
ribonuclear foci (NF). The ribonuclear foci negative and positive nuclei were denoted as NF− (white) and NF+ (red), respectively. Each representative
image is a maximum intensity z projection of the z slice images. For all the conditions (Cas9 + 3′ & 5′-CTGrepeat-gRNA, scrambled gRNA and no Cas9)
enlarged z slices of selected ribonuclear foci negative (NF-) and positive (NF+) nucleus are represented. Nuclei were counter-stained with DAPI (scale
bar = 20 m). (C) Quantification of ribonuclear foci (NF) in CRISPR/Cas9-corrected DM1-iPSC Myo. The total number of ribonuclear foci per total
number of nuclei was calculated. Total of nuclei counted is 6500. The data is represented as mean ± SEM. The statistics were performed using two-tailed
unpaired Student’s t-test (***P<0.001; **P< 0.01; *P< 0.05). (D) Graph shows the % of ribonuclear foci-negative nuclei in the CRISPR/Cas9-corrected
DM1-iPSC-Myo to determine the overall efficiency of CRISPR/Cas9 correction. A total number of 4915 nuclei were examined by FISH staining. The
data is represented as mean ± SEM. The statistics were performed using one-way ANOVA (***P <0.001; **P < 0.01; *P < 0.05). The quantitation was
done in a blinded fashion. (E and F) Graphs showing quantification of ribonuclear foci (NF) in CRISPR/Cas9 corrected DM1 primary myoblasts from
two DM1 patients (VL53 and KN317). The foci per nucleus was calculated and represented by each data point in the graph. The data is represented as
mean ± SEM. The statistics were performed using two-tailed unpaired Student’s t-test (***P <0.001; **P < 0.01; *P < 0.05).
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SMRT sequence data (Supplementary Figures S7A and B)
and previous reports (24).
The amplicons were then subjected to SMRT li-
brary preparation with the appropriate barcoded adap-
tors followed by SMRT sequencing. SMRT sequencing
enabled us to distinguish between three different cate-
gories of DMPK alleles corresponding to: (i) complete
CRISPR/Cas9-dependent excision of the CTG repeat, (ii)
partial CRISPR/Cas9-dependent excision of the CTG re-
peat and (iii) non-edited alleles (either wild-type or mu-
tant). The distribution of these distinct categories of SMRT
sequence reads has been graphically represented in (Fig-
ure 3A, Supplementary Figure S6A and B). Representa-
tive SMRT sequence-reads corresponding to these three dif-
ferent scenarios were shown in Supplementary Figure S6A
(DM1-iPSC-Myo L81/L23) and S6b (DM1-iPSC-Myo
FL5/FL8). The comprehensive SMRT sequencing analy-
sis corroborated our observations based on the DMPK 3′
UTR–specific PCR and the disappearance of the ribonu-
clear foci after CRISPR/Cas9-mediated correction (Fig-
ures 3A–D and 4A; Supplementary Figures S8A–C and
S9). Excision of the CTG repeat expansion could only
be detected in CRISPR/Cas9-corrected DM1-iPSC-Myo
in the presence of 5′-CTGrepeat-gRNA, 3′-CTGrepeat-gRNA
and Cas9. Most of the CRISPR/Cas9-corrected DM1-
iPSC-Myo lines (DM1-L81, DM1-L23, DM1-FL8) yielded
∼40% sequence reads consistent with excision of the CTG
repeat expansion, though this was somewhat lower (∼10%)
in just one of the line (DM1-FL5). The differences corre-
lated well with the differences in nuclear foci between the
various DM1-iPSC-Myo populations (Figure 3B–D; Sup-
plementary Figure S8A–C). Excision of the CTG repeat ex-
pansion was consistent with the presence of indels at the
respective target sites located in proximity of the PAM sites.
In contrast, excision of the entire CTG repeat expansion
or indels could not be detected in the controls (i.e. un-
treatedDM1-iPSC-Myo cells,DM1-iPSC-Myo cells treated
with Cas9 and scrambled gRNA or DM1-iPSC-Myo cells
treated with 5′-CTGrepeat-gRNA, 3′-CTGrepeat-gRNA and no
Cas9). This excludes possible contamination or false posi-
tives. SMRT sequencing confirmed the presence of unedited
wild-type alleles with normal CTG repeats (i.e. 5 CTG re-
peat in DM1-L81, DM1-L23, patient #1; 13 CTG repeat
in DM1-FL8, DM1-FL5, patient #2). Interestingly, partial
deletions of the CTG repeats were also apparent, but again
only in the presence of Cas9 and 5′ & 3′-CTGrepeat-gRNA
and not in the controls without Cas9 or with scrambled
gRNA and Cas9. These partial CTG repeat deletions were
consistent with the presence of indels in proximity of the re-
spective PAM sites and reflect the heterogeneous 3′ DMPK
UTR PCR-amplification pattern (Figure 3A, Supplemen-
tary Figure S6A and B). It is likely that these partial dele-
tions in the CTG repeat are due to a single CRISPR/Cas9-
mediated cut either upstream or downstream of the CTG
repeat resulting in repeat instability. Indeed, such partial re-
peat deletions have also been observed after single target
cleavage with other designer nucleases such as TALENs or
ZFNs (58–60) which results in 5′-3′ resection of the ends
followed by either a replication slippage or homologous re-
combination pathway.
CRISPR/Cas9 has been shown to demonstrate a vari-
able degree of ‘off-target’ cleavage activity (61,62).We there-
fore investigated the extent of potential off-target activity in
the CRISPR/Cas9-corrected DM1-iPSC-Myo. Two puta-
tive off-target sites for each gRNA (5′-CTGrepeat-gRNA and
3′-CTGrepeat-gRNA) (Supplementary Figure S10A and B)
were predicted using a validated computational algorithm
from the Zhang lab (http://crispr.mit.edu/). MiSeq deep se-
quencing was performed on PCR amplicons containing the
target region surrounding these putative computationally
predicted off-target sites. Overall, no detectable off-target
activity above background (i.e. in control condition with-
out Cas9 or with scrambled gRNAs) or only very low level
potential off-target activity ranging between 0.2% and 0.3%
was detected for each of the putative off-target sites of either
5′-CTGrepeat-gRNA or 3′-CTGrepeat-gRNA (Supplementary
Figure S10A and B) consistent with the presence of indels
at the putative off-target sites (Supplementary Table S4).
Biological effects of CRISPR/Cas9 mediated correction of
DM1-iPSC-Myo cells
We subsequently assessed whether the CRISPR/Cas9-
mediated excision of the CTG repeat expansion resulted
in functional correction of the DM1-associated cellu-
lar pathology in DM1-iPSC-Myo. The expression of the
pathogenic CUGexp RNA in DM1-iPSCs or DM1-iPSC-
Myo is associated with accumulation of the ribonuclear foci
(Figure 1B and F). FISH analysis revealed a pronounced
difference in ribonuclear foci accumulation in the nuclei of
CRISPR/Cas9-treated cells compared to controls, based on
nearly 6500 individual nuclei counted (Figure 3B–D; Sup-
plementary Figure S8A–C). In particular, four DM1-iPSC-
Myo lines derived from two different DM1 patients (DM1
patient 1: L81 and L23; DM1 patient 2: FL8 and FL5) were
engineered with the Cas9 and the 5′-CTGrepeat-gRNA and
3′-CTGrepeat-gRNA vectors and exhibited a significant de-
crease in ribonuclear foci. The foci: nucleus ratio ranged be-
tween 1.54 ± 0.09 to 2.2 ± 0.36 in cells treated with Cas9,
5′-CTGrepeat-gRNA and 3′-CTGrepeat-gRNA which was sig-
nificantly decreased (***P < 0.001; **P < 0.01; *P <
0.05) compared to controlDM1-iPSC-Myo cells engineered
with Cas9 and scrambled gRNA (5.29 ± 0.45 to 4.49 ±
0.33) or engineered with only the 5′-CTGrepeat-gRNA and
3′-CTGrepeat-gRNA without Cas9 (5.35 ± 0.28 to 4.50 ±
0.33) (Figure 3B and C; Supplementary Figure S8A–C).
Similarly, a significant proportion of DM1–iPSC-Myo nu-
clei that underwent gene-editing with CRISPR/Cas9 con-
tained no ribonuclear foci (% ribonuclear foci-negative nu-
clei ranged from 38.7 ± 1.7% to 51.9 ± 1.22% between dif-
ferent DM1–iPSC-Myo lines) which was significantly in-
creased (***P < 0.001) compared to control DM1–iPSC-
Myo transduced with Cas9 and scrambled gRNA (% ri-
bonuclear foci-negative nuclei = 0%) or transduced with
5′-CTGrepeat-gRNA and 3′-CTGrepeat-gRNA but no Cas9 (%
ribonuclear foci-negative nuclei = 0%) (Figure 3B and D;
Supplementary Figure S8A–C). The reduction in ribonu-
clear foci after gene editing with CRISPR/Cas9 was consis-
tent with the excision of CTG repeats in theDMPK 3′ UTR
(Figures 2C, D and 3A–C) and with the absence of such foci
in healthy control iPSC or its myogenic iPSC-Myo deriva-
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Figure 4. Biological effects of CRSIPR/Cas9 mediated correction of DM1-iPSC-Myo. (A) Dual staining for MBNL1 and ribonuclear foci co-localization
in the CRSIPR/Cas9-corrected versus control conditions (Cas9 and scrambled gRNA; 5′-CTGrepeat-gRNA, 3′-CTGrepeat-gRNA and no Cas9). Represen-
tative image of DM1-iPSC-Myo stained for MBNL1 and Ribonuclear foci by combined immunostaining-FISH staining. Each representative image is a
maximum intensity z projection of the z slices. For control conditions, enlarged image of selected nuclei are represented under different filters. For the
condition (Cas9 + 3′& 5′-CTGrepeat-gRNA) enlarged z slices of selected ribonuclear foci negative (NF-) and positive (NF+) nucleus are represented under
different filters. Nuclei were counterstained with DAPI. (B) Quantification of the microscopy data is represented in term of ratio between the total dual
positive (MBNL1+RNA+ foci)/total number of nuclei observed in each condition for the L23, L81, FL8 and FL5 DM1-iPSC-Myo cells. The data is
represented as mean ± SEM. The statistics were performed using two-tailed unpaired Student’s t-test (***P <0.001; **P < 0.01; *P < 0.05). (C and D)
Reversal of defective alternative splicing pattern of SERCA in CRISPR/Cas9-corrected DM1-iPSC- derived muscle cells (myocytes/myotubes). Muscle
cells obtained from Cas9 and 5′& 3′-CTGrepeat-gRNA treated DM1-iPSC-Myo was analyzed for alternative splicing with primers specific to exon 21 and
exon 23. The fraction of splice variants either including or excluding exon 22 was quantified based on the band intensity and then plotted. Healthy control
sample (WT), scrambled gRNA and no Cas9 conditions were used as controls. GAPDH was used for normalization. The data is represented as mean ±
SEM. The statistics were performed using two-tailed unpaired Student’s t-test (***P <0.001; **P < 0.01; *P < 0.05).
tive (Figure 1B and D). Conversely, the presence of ribonu-
clear foci in the control conditions (i.e. without Cas9; with
scrambled gRNAs and Cas9) resembled that of uncorrected
DM1-iPSC and DM1-iPSC-Myo cells (Figure 1B and D),
consistent with the presence of the CTG repeat expansion
in the DMPK 3′ UTR locus (Figure 1C and F).
In addition to DM1-iPSC-Myo, we also corrected non-
transformed DM1 patient primary myoblasts, which are
distinct from DM1-iPSC-Myo based on their origin from
satellite cells as discussed previously. These CRISPR/Cas9
treated myoblasts were stained for ribonuclear foci to as-
sess the functional outcome. In accordance with our previ-
ous observation in DM1-iPSC-Myo, a significant decrease
(***P < 0.001) in the average foci/nucleus was also de-
tected in DM1 patient-derived primary myoblasts that were
transduced with Cas9, 5′-CTGrepeat-gRNA and 3′-CTGrepeat-
gRNA vectors as compared to the non-corrected control
conditions (i.e. Cas9 and scrambled gRNA; 5′-CTGrepeat-
gRNA, 3′-CTGrepeat-gRNA and no Cas9) (Figure 3E and
F; Supplementary Figure S6C). Nuclei devoid of ribonu-
clear foci could only be detected in theDM1patient-derived
primary myoblasts that were treated with the Cas9, 5′-
CTGrepeat-gRNA and 3′-CTGrepeat-gRNA vectors and not in
the non-corrected control conditions (i.e. Cas9 and scram-
bled gRNA; 5′-CTGrepeat-gRNA, 3′-CTGrepeat-gRNA and no
Cas9) (Figure 3E and F; Supplementary Figure S6C). It is
therefore particularly encouraging that the reduction in ri-
bonuclear foci after CRISPR/Cas9-mediated gene editing
was consistently observed in DM1 patient-derived primary
myoblasts (from two different DM1 patients) and in all the
four DM1-iPSC-Myo lines (also from 2 different DM1 pa-
tients) (Figure 3C andD).Overall, the functional correction
was relatively efficient in both DM1-iPSC-Myo and DM1
myoblasts, obviating the need for selective enrichment of
these gene-corrected non-transformed cells.
After demonstrating effective correction of the char-
acteristic DM1 genotype and cellular phenotype by
CRISPR/Cas9-mediated excision of the CTG repeats in
the DMPK 3′ UTR, we subsequently examined other
downstream pathways characteristic of DM1, in par-
ticular the MBNL1 sequestration into ribonuclear foci
and SERCA1 alternative splicing. It is known that the
pathogenic CUGexpRNA sequesters the muscleblind-like
protein 1 (MBNL1) in the CUGexpRNA-protein nuclear ag-
gregates of DM1 patient’s cells (38,63). We therefore as-
sessed the localization ofMBNL1 by FISH / immunostain-
ing experiments in CRISPR/Cas9-corrected versus non-
corrected DM1-iPSC-Myo. MBNL1 co-localized with ri-
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bonuclear foci in non-corrected DM1-iPSC-Myo (Figure
4A and B; Supplementary Figure S9). The reduction in
ribonuclear foci after gene editing with CRISPR/Cas9
is consistent with the concomitant delocalization of the
MBNL1 protein. In particular, DM1-iPSC-Myo cells en-
gineered with Cas9, 5′-CTGrepeat-gRNA and 3′-CTGrepeat-
gRNA exhibited a significant decrease in ratio of total num-
ber of co-localized MBNL1+ RNA+ foci to total nuclei
across all four distinct DM1-iPSC-Myo cell populations
(MBNL1+Ribonuclear+ foci: nucleus ratio ranging from
0.41 ± 0.04 to 0.73 ± 0.09) compared to control DM1-
iPSC-Myo cells engineered with Cas9 and scrambled gRNA
(MBNL1+ RNA + foci: nucleus ratio ranging from 1.36
± 0.08 to 1.93 ± 0.26) or engineered with only the 5′-
CTGrepeat-gRNA and 3′-CTGrepeat-gRNA but without Cas9
(MBNL1+ RNA + foci: nucleus ratio ranging from 1.46 ±
0.03 to 1.69 ± 0.25) (Figure 4A and B; Supplementary Fig-
ure S9).
We subsequently determined whether correction of the
CTG repeat expansion by CRISPR/Cas9 and the con-
comitant disappearance of ribonuclear foci could reverse
the aberrant alternative splicing pattern that is char-
acteristic of DM1. The CRISPR/Cas9-corrected DM1-
iPSC-Myo were therefore induced to differentiate into
myocytes/myotubes (Figure 1E) and the differential splic-
ing pattern of SERCA1 was checked. SERCA1 is one of
the known biomarkers of DM1 pathology and exhibits a
characteristic abnormal splicing pattern in DM1 patients.
The exclusion of SERCA1 exon 22 consistently emerged as
the dominant splicing pattern of SERCA1 in DM1 in con-
trast to the predominant inclusion of the SERCA1 exon 22
in wild-type cells (33,45,64). Our current results are con-
sistent with this differential splicing pattern of SERCA1
in DM1 patient versus healthy cells. The DM1-iPSC-Myo-
derivedmyocytes/myotubes showed predominant exclusion
of SERCA1 exon 22 as opposed to its predominant in-
clusion in healthy iPSC-Myo-derived myocytes/myotubes
(Figure 4C andD). Particularly inDM1-iPSC-Myo-derived
myocytes/myotubes, only 0.77± 0.25 to 8.74± 2.64%of the
SERCA1 transcripts correspond to the exon 22 + contain-
ing splice variant whereas this increased to 75.29 ± 6.34 to
82.34 ± 2.34% in myocytes/myotubes derived from healthy
iPSC-Myo cells. CRISPR/Cas9-mediated excision of the
CTG repeats expansion from the DMPK 3′ UTR in DM1-
iPSC-Myo-derived myocytes/myotubes resulted in the nor-
malization of the SERCA1 splicing pattern, more similar
to that of healthy iPSC-Myo-derived myocytes/myotubes.
This is consistent with a significant increase in exon 22 in-
cluded splice variant after gene editing of the DMPK gene
with Cas9, 5′-CTGrepeat-gRNA and 3′-CTGrepeat-gRNA (7.46
± 0.53% to 40.39± 3.34%) compared to controls with-
out Cas9 (1.55 ± 0.11% to 3.2 ± 0.87%) or with scram-
bled gRNA and Cas9 (2.2 ± 0.10% to 4.2 ± 2.3%). Con-
versely, in the absence of Cas9 or when scrambled gRNAs
were employed, the exclusion of exon 22 emerged as the pre-
dominant splice variant, similar to the splicing pattern of
non-treated DM1-iPSC-Myo-derived myocytes/myotubes
(Figure 4C and D). Taken together, these results demon-
strate that theCRISPR/Cas9-mediated excision of theCTG
trinucleotide repeat expansion in DM1-derived myogenic
cells was effective in reversing the DM1 phenotype in the
DM1-iPSC-Myo cells and their differentiated derivatives
(myocytes/myotubes).
After demonstrating effective functional corrections
in the CRISPR/Cas9-treated cell populations, we as-
sessed the stability of DMPK transcripts. To demon-
strate that the CRISPR/Cas9-medated excision of the
CTG repeat in the 3′ UTR region did not affect the
DMPK mRNA stability, a quantitative reverse transcrip-
tase PCR (qRT-PCR) was performed to detect DMPK
mRNA levels in the CRISPR/Cas9-corrected DM1-iPSC-
Myo cells after differentiation into myocytes/myotubes
and in its respective non-corrected DM1-iPSC-Myo-
derived myocytes/myotubes controls (i.e. Cas9 and scram-
bled gRNA; 5′-CTGrepeat-gRNA, 3′-CTGrepeat-gRNA and no
Cas9). The qRT-PCR was designed based on primers that
amplify the junction of exon 10–11 until exon 12 of the
DMPK gene. Our results demonstrated that there was no
significant difference in the DMPK mRNA expression lev-
els in the CRISPR/Cas9-corrected DM1-iPSC-Myo cells
as compared to the non-corrected DM1-iPSC-Myo control
cells (Supplementary Figure S8D).
CRISPR/Cas9-correction of DM1-iPSCs
The CRISPR/Cas9-corrected DM1-iPSC-Myo population
is heterogeneous with respect to the expanded CTG repeat
excision pattern, consistent with the SMRT analysis (Fig-
ure 3A, Supplementary Figure S7A and B). Different sce-
narios can be envisaged that account for this heterogene-
ity. This may possibly reflect CTG repeat excision of the
mutant, wild-type or even both DMPK alleles, since the
CRISPR/Cas9 strategy cannot distinguish between both.
Alternatively, in some cells none of the alleles would be af-
fected. Ideally, to formally demonstrate this, it would be re-
quired to analyze CTG repeat excision on individual clones
derived from the CRISPR/Cas9-treated DM1-iPSC-Myo
population by Southern blot analysis. However, we could
never obtain individual clones by limiting dilution, which
likely reflects the non-transformed nature and intrinsic bi-
ology of these differentiated mesoangioblast-like cells. To
overcome this limitation, we decided to therefore conduct
Southern blot analysis on individual iPSC clones derived
from CRISPR/Cas9-corrected DM1-iPSCs. To introduce
the CRISPR/Cas9 components into the DM1-iPSCs we
initially relied on the use of lentiviral vectors as was used
successfully for the DM1-iPSC-Myo cells. However, lentivi-
ral transduction of the DM1-iPSCs was not as efficient
as in the case of DM1-iPSC-Myo cells. Moreover, to de-
liver the CRISPR/Cas9 components into the DM1-iPSCs
it may be desirable to use a non-integrating non-viral de-
livery method instead, to eliminate the risk of insertional
oncogenesis associated with random genomic integration.
We therefore explored the use of a non-viral gene correction
method based on nucleofection of ribonucleoprotein (RNP)
complexes composed of Cas9 proteins and synthetic single
guide gRNA (sgRNA).
As mentioned previously, a total of four DM1-iPSC
lines were generated from 2 different DM1 patients (desig-
nated as L23, L81 from DM1 patient #1; FL5, FL8 from
DM1 patient #2). These DM1-iPSC lines (n = 4) were
transfected with RNP-CRISPR/Cas9 complexes consist-
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ing of Cas9 protein, 5′-CTGrepeat-sgRNA and 3′-CTGrepeat-
sgRNA. This was repeated in 3 independent experiments
(i.e. 4 × 3 = 12). Delivery of RNP complex consisting of
Cas9 protein and the corresponding synthetic single gRNA
(sgRNA) into the DM1-iPSCs consistently resulted in a sig-
nificant decrease in ribonuclear foci (based on≈1500 nuclei
counted). In particular, the foci: nucleus ratio ranged be-
tween 0.92 ± 0.37 to 1.23 ± 0.38 which was significantly
decreased (***P< 0.001; **P< 0.01; *P< 0.05) compared
to control DM1-iPSCs cells transfected with RNP com-
plexes containing Cas9 and scrambled sgRNA (5.44 ± 0.78
to 6.40 ± 0.41) or transfected with 5′-CTGrepeat-sgRNA and
3′-CTGrepeat-sgRNA without Cas9 protein (4.64 ± 0.26 to
5.88 ± 0.15) (Figure 5A; Supplementary Figure S11A–D).
Similarly, a significant proportion of DM1–iPSCs nuclei
that underwent gene-editing with the RNP-CRISPR/Cas9
complexes contained no ribonuclear foci (% ribonuclear
foci-negative nuclei ranged from 59.84 ± 3.9% to 67.9 ±
2.35% between different DM1–iPSCs lines) which was sig-
nificantly increased (***P < 0.001) compared to control
DM1–iPSCs transfected with RNP complexes containing
Cas9 and scrambled sgRNA (% ribonuclear foci-negative
nuclei = 0%) or only sgRNA 5′-CTGrepeat-sgRNA and 3′-
CTGrepeat-sgRNA but no Cas9 protein (% ribonuclear foci-
negative nuclei = 0%) (Figure 5B; Supplementary Figure
S11A–D). The reduction in ribonuclear foci after gene edit-
ing with CRISPR/Cas9 was consistent with the previous
data on excision of CTG repeats in DM1-iPSC-Myo cells
and DM1 myoblasts. Conversely, the presence of ribonu-
clear foci in the control conditions (i.e. without Cas9 pro-
tein; or with scrambled sgRNA and Cas9 protein) resembled
that of uncorrected DM1-iPSCs and DM1-iPSC-Myo cells
(Figure 1B and D), consistent with the presence of theCTG
repeat expansion in the DMPK 3′ UTR locus (Figure 1C
and F).
Triplet repeat primed PCR and ribonuclear foci analysis of
individual CRISPR/Cas-corrected DM1-iPSC clones
Single-cell clones were obtained by limiting dilution from
the DM1-iPSC populations derived from each of the four
lines (L23, L81 fromDM1 patient #1; FL5, FL8 fromDM1
patient #2) nucleofected with the RNP-CRISPR/Cas9
complexes. Ribonuclear foci staining and triplet repeat
primed PCR (TP-PCR) analysis of a total of 161 individ-
ual clones isolated from the four DM1-iPSCs lines trans-
fected with the RNP-CRISPR/Cas9 complexes revealed
that 142 clones were corrected and 19 were non-corrected.
In particular, TP-PCR analysis revealed a pronounced dif-
ference in the TP-PCR signal intensity plots (i.e. electro-
pherograms) of the corrected DM1-iPSC clones compared
to untreated DM1-iPSC controls. In contrast, the electro-
pherograms of the non-corrected DM1-iPSC clones were
similar to the electropherograms obtained from untreated
DM1-iPSC controls. Representative electropherograms are
shown (Figure 5E; Supplementary Figure S12A and B).
Analysis of ribonuclear foci staining revealed that the cor-
rected DM1-iPSC clones were devoid of ribonuclear foci
as compared to non-corrected clones, where we could de-
tect presence of ribonuclear foci. Representative ribonuclear
foci FISH staining (maximum intensity z projection of z
slices) of corrected vs. non-corrected DM1-iPSC clones are
shown (Figure 5F; Supplementary Figure S13). The ribonu-
clear foci staining of the individual clones were entirely con-
sistent with the electropherogram results.
Southern blot analysis and target region sequencing of indi-
vidual CRISPR/Cas-corrected DM1-iPSC clones
Subsequently, based on the TP-PCR and ribonuclear foci
analysis using FISH (Figure 5E and F; Supplementary Fig-
ures S13 and S12A, B), we selected a total of 23 (17 cor-
rected and 6 non-corrected)DM1-iPSC clones for Southern
blot analysis to confirm the excision of the expanded CTG
repeat. A probe specific for the DMPK 3′ UTR region that
harbors the expanded CTG repeat was employed (Supple-
mentary Figure S4A).
The Southern blot analysis demonstrated that the cor-
rectedDM1-iPSC clones (FL8: c14, c10, c09, c07; FL5: c17,
c13, c12, c05; L81: c25, c19, c14, c10, c06; L23: c30, c10,
c03, c01) lacked the characteristic mutated expanded allele
(mut) containing the expanded CTG repeat as compared to
their respective non-correctedDM1-iPSC clones (FL8: c35,
c01; FL5: c28; L81: c08; L23: c32, c06) (Figure 5C). The dis-
appearance of the large-sized bands in the corrected DM1-
iPSC clones is consistent with the lack of large-sized bands
in healthy iPSC controls. There is a well-known polymor-
phism in theDMPK locus that can be attributed to the pres-
ence or absence of an Alu repeat (4,52,53). This Alu poly-
morphism accounts for the presence of two distinct bands
in the healthy iPSC controls. Hence, one of the wild-type
DMPK alleles in the healthy iPSC control contains an Alu
repeat (designated as Alu+) whereas the Alu repeat was ab-
sent in the other wild-type allele (designated as Alu-). Sim-
ilarly, in the corrected DM1-iPSC clones derived from FL8
(c14, c10, c09, c07) and FL5 (c17, c13, c12, c05) DM1-
iPSCs, we could detect two distinct bands corresponding to
the polymorphic Alu+ and Alu- wild-type DMPK alleles,
consistent with the same two bands in healthy iPSCs (Fig-
ure 3C). The corrected DM1-iPSC clones derived from L81
DM1-iPSCs (c25, c19, c14, c10, c06) and L23 DM1-iPSCs
(c30, c10, c03, c01) had a single band that corresponded
to the upper (Alu+) band from healthy iPSC controls (Fig-
ure 5C). The non-corrected DM1-iPSC clones (L81: c08;
L23: c32, c06; FL8: c35, c01; FL5: c28) were heterozygous
and contained a mutated DMPK allele (denoted as mut)
with a characteristic CTG repeat expansion and a wild-
typeDMPK allele (denoted as wt) (Figure 5C). CTG repeat
expansion in the non-corrected DM1-iPSC clones derived
from FL8 and FL5 (FL8: c35, c01; FL5: c28) ranged from
∼1400 to ∼1700 repeats, whereas in case of L81 and L23
(L81: c08; L23: c32, c06) the range was between ∼1100 to
∼1800 repeats. The L23-c32 exhibited two repeat sizes (Fig-
ure 5C), which may be attributed to repeat instability in-
curred during the clonal expansion, as reported previously
(48–51). The Southern blot analysis was consistent with the
results obtained by TP-PCR and ribonuclear foci analysis,
providing direct proof that the CRISPR/Cas9-mediated ex-
cision of the expanded CTG repeats in DM1-iPSC cells re-
sulted in phenotypic correction.
Subsequently, we selected one corrected clone from each
of the four DM1-iPSCs (L81: c10; L23: c03; FL8: c09,
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Figure 5. Analysis of CRISPR/Cas9 corrected DM1-iPSCs and isolated DM1-iPSC clones by Southern blot assay, target region sequencing, TP-PCR
and ribonuclear foci staining. (A) Quantification of ribonuclear foci (NF) in CRISPR/Cas9-corrected DM1-iPSCs. The total number of ribonuclear foci
per total number of nuclei was calculated. Total of nuclei counted is 1500. The data is represented as mean ± SEM. The statistics were performed using
two-tailed unpaired Student’s t-test (***P<0.001; **P< 0.01; *P< 0.05). (B) Graph shows the % of ribonuclear foci-negative nuclei in the CRISPR/Cas9-
corrected DM1-iPSCs to determine the overall efficiency of CRISPR/Cas9 correction. A total number of 1500 nuclei were examined by FISH staining.
The data is represented as mean ± SEM. The statistics were performed using one-way ANOVA (***P <0.001; **P < 0.01; *P < 0.05). (C) Southern blot
analysis to detect the presence of expanded trinucleotide CTG repeat region in 23 DM1-iPSC clones isolated from four DM1-iPSC lines derived from two
DM1 patients (L81 and L23; FL8 and FL5) and healthy control iPSCs. EcoRI digested genomic DNA was subjected to agarose gel electrophoresis and
probed to detect the DMPK locus. (mut=mutant; wt= wild type). (D) Representative sequences obtained from sanger sequencing of target locus in each
of the four selected DM1-iPSC clones (L23: C03, L81:C10, FL8:C09 and FL5:C12). For ease of alignment we have placed a reference sequence with 5′ and
3′-CTGrepeat-gRNA target sites (green and blue) and protospacer adjacent motif (PAM) region (red) highlighted. In the sequence alignment deleted region
has been marked with (–) and insertions highlighted in lowercase. (E) Representative electropherograms of Triplet Repeat Primed PCR (TP) products
from DM1-iPSC clones (corrected clone: L23 C03; non-corrected clone: L23 C32) isolated after CRISPR/Cas9-mediated gene editing. (F) Representative
images of a corrected (L23 C03) and non-corrected (L23 C32) DM1-iPSC clone stained for ribonuclear foci. An antisense Cy3-labeled probe was used to
detect the presence of ribonuclear foci (NF). The ribonuclear foci negative and positive nuclei were denoted as NF− (white) and NF+ (red), respectively.
Nuclei were counter-stained with DAPI (scale bar = 20 m). Each representative image is a maximum intensity z projection of the z slices. For both clones
enlarged z slices of selected ribonuclear foci negative (NF–) or positive (NF+) nucleus are represented.
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c07; FL5: c12) for target region sequencing of both DMPK
alleles in each clone. The target region was PCR ampli-
fied, cloned and sequenced by Sanger sequencing. Typi-
cally, up to 16 cloned amplicons were sequenced for each
clone. The sequencing results (Figure 5D) confirmed exci-
sion of the expanded CTG repeat in the CRISPR/Cas9-
corrected DM1-iPSC clones. This is consistent with the
CRISPR/Cas9-induced double-strand DNA cut and indel
formation in close proximity to the consensus NGG PAM
sequences that are located upstream and downstream of
the expanded CTG repeat (Figure 5D). Two possible se-
quences could be retrieved for each of the clones, indicat-
ing that CRISPR/Cas9 targeted both the mutant and wild-
type DMPK alleles. The consequences of excising the CTG
repeat from the 3′UTR of the wild-type DMPK allele are
unknown. If future studies would reveal some unintended
consequences, then further fine-tuning of the editing strat-
egy may ultimately be needed to achieve allele-specific gene
editing. Overall, the consistency of the data obtained by
Southern blot analysis, Sanger sequencing, TP-PCR and ri-
bonuclear foci analysis (FISH) validates each of thesemeth-
ods and underscores the robustness of this comprehensive
analysis.
DISCUSSION
Advances in genome engineering have led to gene editing
tools being increasingly used for addressing monogenic ge-
netic disorders. This has revolutionized the field of gene
therapy in making important strides forward in the treat-
ment of recessive genetic diseases, which has recently wit-
nessed several gene therapy products receiving regulatory
approval (65–67). Monogenic recessive diseases that result
in a loss-of-function associated with a specific mutation
can be corrected by the addition of a functional wild-type
copy of the cognate mutated gene. However, treating dom-
inant genetic disorders by addition of a functional gene
copy will neither suffice to compensate for the genetic de-
fect nor reverse the underlying pathology. Instead, spe-
cific inactivation of the dominant gain-of-function allele
is required, which is more challenging. The emergence of
programmable, nucleotide-specific gene-editing technolo-
gies based onCRISPR/Cas9 opens new perspectives to cor-
rect such dominant genetic disorders.
In the current study, we established proof-of-concept
using a cellular disease model whereby a dominant ge-
netic defect (i.e. DM1) could be specifically corrected us-
ing CRISPR/Cas9. Skeletal muscle dysfunction represents
one of the main clinical manifestations of DM1. To val-
idate CRISPR/Cas9 for gene editing of DM1, we there-
fore relied not only on DM1 patient-specific primary my-
oblasts but also on DM1 patient-specific iPSCs and DM1-
iPSC-derived myogenic cells (27). DM1 myoblasts, DM1-
iPSCs and DM1-iPSC-Myo cells distinguish themselves
from healthy cells by the nuclear accumulation of ribonu-
clear foci. This was consistent with the abnormal seques-
tration of MBNL1 and the aberrant splicing pattern (e.g.
SERCA1) in case of the terminally differentiated myotubes
and myocytes. Consequently, these DM1 patient-specific
myogenic cellular models replicates many of the key fea-
tures of DM1 in vitro and may therefore prove useful to
validate new therapeutic strategies (in casu gene editing)
or to ultimately gain a deeper understanding of the un-
derlying pathophysiological mechanisms of DM1. One of
the main strengths of the current proof-of-concept study is
that it is based on DM1 patient-derived myogenic cells, ca-
pable of muscle tissue regeneration and replicating muscle
function in vitro. They could potentially be used to replace
dysfunctional and degrading muscle tissue in an autolo-
gous setting (26,27). These DM1 patient-derived myogenic
cells are non-transformed and offer an attractive model sys-
tem to better understand and characterize the genetic and
cellular consequences of CRISPR/Cas9-mediated target-
ing at the DMPK locus, as shown in the current study.
Though transformed cell lines could be considered as al-
ternatives, it is well established that they typically tend to
skew the overall gene targeting efficacies and often have ab-
normal DNA repair characteristics, raising questions over
their clinical relevance (68,69). Moreover, the cellular con-
sequences of gene correction may differ compared to when
non-transformed cells are employed (70,71). The availabil-
ity of this DM1-iPSC-Myo cellular model therefore com-
plements the use of alternative DM1 disease-specific trans-
formed cell lines (68,69,72–76).
To correct the mutant DMPK allele encoding the
pathogenic CUGexpRNA, we designed a strategy that relied
on a dual gRNA approach to target the flanking regions
just 5′-upstream and 3′-downstream of the CTG repeat ex-
pansion. This likely caused a Cas9-mediated double-strand
DNA break at the respective sites in the DMPK locus in
close proximity to the PAM consensus sequence, followed
by the subsequent excision of the entire ∼ 4.1 kb CTG re-
peat and re-ligation of the juxtaposed DNA fragments, in
agreement with the sequencing data obtained by Sanger
and SMRT sequencing. In particular, we also demonstrate
that the large >1200 trinucleotide (CTG) repeat expansion
could be excised with relatively high efficiency and fidelity
by CRISPR/Cas9, obviating the need for further selective
enrichment of gene-edited cells (69). Most importantly, by
excising the CTG expanded repeats in the DMPK 3′ UTR,
the DMPK protein coding sequence itself remained un-
changed and the DMPK mRNA expression level remained
unchanged. Moreover, instead of relying on a single gRNA
as this would increase the likelihood of obtaining mainly
partial deletions of the CTG repeat, our strategy ensured
complete excision of trinucleotide repeat region. This dis-
tinguishes the current approach from previous gene edit-
ing attempts based on homologous directed repair (HDR)
using TALENs that resulted in a truncated DMPK pro-
tein and were overall less efficient compared to the current
approach (77,78). Consequently, CRISPR/Cas9-mediated
deletion of theCTG repeat results in a functional correction
of the quintessential DM1 disease manifestations at the cel-
lular andmolecular level, consistent with the disappearance
of the ribonuclear foci, restoration of MBNL1 sequestra-
tion and correction of the spliceopathy based on SERCA1
splicing. SERCA1 in particular has been found to be asso-
ciated with impaired Ca2+ homeostasis in DM1muscle that
may account, at least in part, to the abnormal muscle func-
tion (33).
The molecular consequences of the CRISPR/Cas9-
mediated excision of the CTG repeat in the DMPK 3′UTR
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were analyzed by TP-PCR, Sanger sequencing, single-
molecule real-time (SMRT) sequencing and Southern blot
analysis, providing direct evidence of CTG repeat exci-
sion in the DMPK target locus. The results were consis-
tent across the different assays used. SMRT sequencing by-
passes critical limitations of conventional technologies in
the context of highly repetitive conditions such as trinu-
cleotide expansions, even enabling detection of minor al-
lelic variants that occur at lower frequency. In particular,
measurements from isolated molecules overcome the prob-
lems of sample heterogeneity and diminishing resolution in-
herent in bulk sequencing approaches (56,79). Moreover,
SMRT sequencing has a higher accuracy and is able to se-
quence through large (tandem) repeats compared to exist-
ing ‘next generation’ sequencing platforms (56,57). Indeed,
we have previously used and validated this method to de-
tect AGG interruptions in the quintessential CGG repeat
expansion of the FMR1 gene (79). To our knowledge, our
current study is the first to implement SMRT sequencing
technology to characterize the CTG repeat expansion in
DM1 after CRISPR/Cas9-mediated gene editing. We be-
lieve that this represents a technological advancement over
existing methodologies with broader implications for the
gene-editing field at large and for triplet nucleotide repeat
expansion in particular. Moreover, SMRT also obviates
concerns associated with the use of internal primers that
bind within the CTG repeat sequence, as in the case of TP-
PCR.
SMRT sequencing allowed us to readily distinguish wild-
type uncut alleles from targeted DMPK alleles (wild-type
ormutant). In some cases, it was possible to unambiguously
demonstrate targeting of thewild-type allele due to the pres-
ence of indels in proximity of the respective PAM sites lo-
cated upstream or downstream of the normal CTG repeat
with the characteristic low number of repeats (wild-type al-
lele in 2 patients: 5 or 13 repeats) (Supplementary Figures
S7A and S7B). Similarly, it was also possible to demonstrate
targeting of the mutant allele due to the presence of indels
in proximity of the respective PAM sites located upstream
or downstream of the CTG repeat expansion (Supplemen-
tary Figures S7A and S7B). Using SMRT sequencing we
could not discriminate between excisions of the CTG re-
peat in mutant versus wild-type alleles. However, only ex-
cision of the pathogenic expanded CTG repeat (and not of
the wild-type CTG repeat) would have resulted in ribonu-
clear foci negative nuclei or an overall decrease in ribonu-
clear foci: nucleus ratio. Hence, the number of ribonuclear
foci-negative cells provide a reliable means to assess the net
effect of the CRISPR/Cas9-mediated CTG repeat excision
of the pathogenic allele and does not take into account the
effect of CRISPR/Cas9-medaited excision of the CTG re-
peat in wild-type allele.
To better understand the consequences of the
CRISPR/Cas9 editing onCTG repeat excision of wild-type
vs. mutant DMPK alleles, we conducted Southern blot
analysis on individual clones derived from CRISPR/Cas9-
corrected DM1-iPSCs. To introduce the CRISPR/Cas9
components into the DM1-iPSCs we explored the use of a
non-viral gene correction method based on nucleofection
of ribonucleoprotein (RNP) complexes composed of Cas9
proteins and synthetic single guide gRNA (sgRNA). This
overcomes the limitations of using lentiviral vectors for
delivery of CRISPR/Cas9 components and therefore
eliminates the risk of insertional oncogenesis. Remarkably,
robust correction efficiencies upto 90% could be attained in
DM1-iPSCs as confirmed at the clonal level by ribonuclear
foci analysis following ribonucleoprotein (RNP) trans-
fection of CRISPR/Cas9 components without the need
for selective enrichment. Most importantly, Southern blot
analysis confirmed that the phenotypic correction was due
to excision of the expanded CTG repeat.
Southern blot analysis, SMRT sequencing, allele-specific
PCR and Sanger sequencing of target region (Figures 3A,
2D, 5C and D; Supplementary Figures S6B–C, S7A–B) ex-
perimentally also demonstrated that both the mutant and
wild-typeDMPK 3′UTR had undergone specific editing by
CRISPR/Cas9 in both cellular models (i.e. DM1-iPSCs or
DM1-iPSC-Myo). This is consistent with the fact that the
gRNAs used to target the sequences upstream and down-
stream of the CTG repeat were identical between the wild
type andmutantDMPK alleles.Hence, based on the current
CRISPR/Cas9 strategy, it was not possible to obtain spe-
cific excision of the CTG repeat only in the mutant DMPK
allele and not in the wild-type allele. However, it is reas-
suring that excision of the CTG repeat in either the wild
type or mutant DMPK locus does not result in any mu-
tation of the DMPK protein itself, since the repeat is lo-
cated in the 3′UTR. Moreover, qRT-PCR demonstrated
that CRISPR/Cas9-mediated excision of the CTG repeat
did not affect the steady-state DMPK mRNA levels (Sup-
plementary Figure S8D).
In conclusion, CRISPR/Cas9-mediated excision of the
CTG repeat sequences in the wild type or mutant DMPK
alleles might not result in any qualitative or quantitative dif-
ferences in DMPK protein expression minimizing the risk
of untoward side effects. Nevertheless, a targeting strategy
specific for the mutant DMPK allele would still be pre-
ferred. This could potentially be achieved by exploiting the
presence of single nucleotide polymorphisms (SNPs) that
discriminate the wild type from mutant DMPK alleles. In
particular, the occurrence of SNPs in the NGG consensus
PAM site provides a particularly attractive strategy to de-
velop an allele-specific targeting approach that discrimi-
nates between wild type and mutant alleles (80). One lim-
itation of this approach however, in contrast to our current
strategy, is that it would not be generally applicable to all
DM1 patients since it would depend on specific SNPs. Tar-
geting the gRNAs to the CTG repeat region itself or to the
junction would not have made sense since it would likely
also result in the targeting of many other genes with CTG
repeats, resulting in potential off-target effects.
Taken together, our results suggest that CRISPR/Cas9 is
an attractive platform to potentially correct dominant ge-
netic diseases by robust gene editing, including other dis-
orders caused by large nucleotide repeat expansion, such
as Huntington’s disease, spinocerebellar ataxia and fragile
X syndrome. To our knowledge, there are several novel as-
pects associated with our study. Our study achieves triplet
repeat excision in patient-derived iPSCs and differentiated
myogenic cells (as opposed to immortalized cell lines). Sub-
stantially higher correction efficiencies (i.e. at least 40-fold
higher) were attained in the present study (up to 90% us-
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ing CRISPR/Cas9-sgRNA RNP complex transfection of
DM1-iPSCs) compared to the relatively modest correction
efficiencies recently reported in fragile X syndrome (FXS)
iPSCs or ES cells (24). In that study only 2 to 3 edited
iPSC or ESC-derived clones with CGG repeat deletions
were established out of approximately 100 clones (2–3% ef-
ficiency). In our study relatively high correction efficien-
cies obviate the need to screen and selectively pick individ-
ual clones (69), which is not always possible with primary
cells, without inducing cellular transformation (as in the
case of mesangioblasts or iPSC-Myo cells). Moreover, the
correction of abnormal CTG repeat expansion in DM1 was
achieved without the use of a wild-type allele or the use of
an exogenous donor sequence, but rather through NHEJ
induced by the Cas9 nuclease, eliminating the need for se-
lective enrichment of homologous recombinants (81).
The aforementioned Park et al. study (24) focuses on
fragile X syndrome (FXS), an X-linked neurological dis-
order, resulting from a CGG repeat expansion in the frag-
ile X mental retardation 1 (FMR1) gene. It is clearly dis-
tinct in terms of its underlying pathological mechanisms,
disease manifestations and affects distinct target tissues and
organs compared to DM1. Indeed, our current study is
complementary to the study of Park and colleagues (24)
as it shows the impact of gene editing of triplet repeats on
the spliceopathy, intrinsic to DM1 in muscle cells, as op-
posed to the reversion of FMR1 promoter methylation in
the selected clones upon neuronal differentiation (24). We
demonstrated CRISPR/Cas9-mediated excision of trinu-
cleotide repeat expansions that extend upto >1200 repeats
(corresponding to >3600 nucleotides). To achieve this, we
had designed a dual gRNA strategy to target the flanking
regions just 5′-upstream and 3′-downstream of the CTG re-
peat expansion. The approach described by Park et al., re-
lied on just a single gRNA upstream of the CGG repeat
sequence of the FMR1 gene which is a much more con-
tracted repeat expansion (i.e. 200–450 repeats) (24). It seems
unlikely that this single gRNA-based strategy described by
Park et al. would have sufficed to obtain efficient excision
of the very large extended repeat expansions in the DMPK
locus. The deletion triggered by just a single Cas9-induced
double-strand DNA break, would have to encompass the
entire CTG repeat region (i.e. > 3600 nucleotides).
Based on the relative transduction efficiencies of the Cas9
and gRNA lentiviral vectors, we estimated that the percent-
age of DM1-iPSC-Myo cells containing the 3 vectors cor-
responded to ∼70–80%. Hence, the requirement for triple
co-transduction to obtain efficient CTG repeats excision
explains, at least in part, why the decrease in ribonuclear
foci could not attain 100%. Nevertheless, considering over-
all gene correction efficiencies over 50% (Figure 3B, C and
D; Supplementary Figure S8A-C) and taking the actual
transduction efficiencies into account, this would imply that
nearly 80% of the DM1-iPS-Myo cells that contained the
3 vectors (i.e. Cas9, 5′-CTGrepeat-gRNA and 3′-CTGrepeat-
gRNA vectors) were actually phenotypically corrected. To
further improve the overall gene editing efficiency, future
studies should ideally incorporate the Cas9, 5′-CTGrepeat-
gRNA and 3′-CTGrepeat-gRNA expression cassettes into a
single vector backbone, obviating the need for triple lentivi-
ral co-transductions or by using CRISPR/Cas9-sgRNA
RNP transfections as shown in the current study.
Although our results with excising repeats show great
promise, an important question for future studies is the need
to address the induction of off-target mutations. This would
need to be addressed prior to use of any CRISPR-Cas9
based strategy for therapeutics. Recent work has described a
number of genome-wide methods for identifying off-target
effects of CRISPR-Cas9 nucleases (82–87). In this study,
we examined relatively small number of potential off-target
sites predicted by an in silico program for mutations as
judged by targeted next-generation sequencing. Although
this approach yielded encouraging result that no indel mu-
tations were found at these sites, we acknowledge and are
aware of limitations in the capability of the in silico program
we used to identify bona fide off-target mutations (83). Our
future work will therefore focus on implementing genome-
wide strategies, like GUIDE-seq or CIRCLE-seq (83,88),
whichwillmore comprehensively assess for off-target effects
induced by pairs of gRNAs used in our studies. Alterna-
tively, whole-genome sequencing (WGS) could be used to
assess the presence of indels and single nucleotide variants
(SNVs). Indeed, a recent study demonstrated that WGS
analysis of both indels and SNVs as the most thorough
method for identifying off-target mutations and showed an
unexpectedly high number of SNVs compared to the widely
accepted assumption that CRISPR causes mostly indels at
regions homologous to the gRNA (89). Nevertheless, this
study is somewhat controversial since published sequence
data were used as reference rather than use of a control mice
not injectedwith theCas9 protein [(Wilson et al.- The exper-
imental design and data interpretation in ‘Unexpected mu-
tations after CRISPRCas9 editing in vivo’ by Schaefer et al.
are insufficient to support the conclusions drawn by the au-
thors. BioRxiv, 2017; doi: https://doi.org/10.1101/153338)].
Moreover, that study was underpowered as it was based on
a limited number of animals. Given this caveat it is challeng-
ing to tease out which variants are due to the natural genetic
variation caused by genetic drift that pre-existed prior to the
CRISPR treatment and which ones are CRISPR-related.
Additionally, we note that it may be possible to further en-
hance on-target editing and minimize the risk of putative
off-target effects by implementing our strategy using the
latest generation of higher-fidelity CRISPR/Cas9 systems
(90,91), whichwere developed and described as wewere car-
rying out the current study.
It has been shown that CRISPR/Cas9-mediated cleav-
age could potentially result in chromosomal translocations
(92–94). Hence, it cannot be excluded that cleavage of the
wild type and mutant DMPK allele could trigger translo-
cations between homologous chromosomes carrying either
the wild type or mutant DMPK allele. This would recreate
the wild type or mutant DMPK allele, and would dilute off
any net benefit. Indels could potentially be incorporated at
the translocation site but since this site is expected to be lo-
cated in the 3′UTR it is unlikely that this would trigger seri-
ous adverse consequences.Nevertheless, reciprocal chromo-
somal translocations could potentially also occur between
the actual target site and any off-target sites that may result
in unexpected, potentially adverse effects.
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Targeting the CTG repeat in the 3′UTR of the DMPK
gene by CRISPR/Cas9 complements previous therapeu-
tic strategies that are typically focusing on inhibiting the
CUGexp RNA instead (95–100). Prior to moving towards
clinical applications in DM1 patients it is important to first
demonstrate that DM1 patient-derived muscle cells could
be corrected by CRISPR/Cas9. This has now been demon-
strated in the current study using both primary myoblasts
as well as myogenic cells derived fromDM1 patient-specific
iPSCs. Future in vivo gene editing approaches in DM1 pa-
tients will likely result in the editing of resident myogenic
stem cells in the muscle tissues (21). Hence, it is particularly
important to establish proof of concept that CRISPR/Cas9
can phenotypically correct myogenic cells from DM1 pa-
tients since they could contribute significantly to muscle re-
pair and potentially enhance the overall efficacy of the gene
editing strategy. Therefore, it is particularly encouraging
that relatively robust gene correction efficiencies could be
attained in such non-transformed DM1 cell lines, which are
more representative of what could be expected in primary
cells or myogenic progenitor cells in human. This would
allow us to investigate the consequences of transient ex-
pression of the CRISPR/Cas9 components on the overall
targeting efficiency of the expanded CTG repeat compared
to what can be achieved with bona fide integrating vectors
as a benchmark. Moreover, we could substitute the use of
retroviral vectors for reprogramming with potentially safer
methods based on non-integrating vectors instead (101–
103). The nature of the reprogramming protocol is unlikely
to have any effect on the outcome of the DMPK targeting
itself with CRISPR/Cas9.
In the next stage, it will be equally important to demon-
strate that CRISPR/Cas9 could be used to correct theDM1
disease phenotype in vivo in a preclinical animal model that
mimics the cognate human disease. Several transgenic DM1
mouse models have been generated based on the inclusion
of a CTG repeat expansion in the DMPK locus (104–106).
These preclinical models replicate some of the pathologi-
cal features of DM1 observed in patients and are there-
fore well suited to assess the efficacy of CRISPR/Cas9-
based excision of the CTG repeat in vivo. It is also promis-
ing that recent studies have exhibited that the triplet re-
peat expansion in the huntington (HTT) locus could be
excised by CRISPR/Cas9-based gene editing in a mouse
model of Huntington’s disease (107). This further accentu-
ates the potential of using CRISPR/Cas9 for in vivo gene
editing of DM1, which we are now going to assess in a
DM1mouse model. This may ultimately lead to a new clin-
ically relevant approach for DM1 by in vivomuscle-directed
CRISPR/Cas9-mediated gene editing (18,19,21,108).
SUPPLEMENTARY DATA
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